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Binding of GnRH to its receptor (GnRHR) stimulates the synthesis and secretion 
of the gonadotropins, as well as up-regulation of GnRHR.  Thus, the interaction between 
GnRH and GnRHR represents a central point for regulation of reproduction.  
Glucocorticoids alter reproduction by reducing GnRH responsiveness of gonadotropes 
within the anterior pituitary gland, potentially via transcriptional regulation of the 
GnRHR gene.  Investigation into this mechanism, however, revealed that the murine 
GnRHR gene was stimulated by glucocorticoids.  To determine the effect of 
glucocorticoids on porcine GnRHR gene expression, gonadotrope-derived αT3-1 cells 
were transiently transfected with a vector containing 5118 bp of 5’ flanking sequence for 
the porcine GnRHR gene fused to luciferase for 12 h and treated with increasing 
concentrations of the glucocorticoid agonist, dexamethasone (0, 1, 10, 100 and 1,000 nM) 
for an additional 12 h prior to harvest.  Maximal induction of luciferase activity was 
detected at 100 nM of dexamethasone (2-fold over vehicle; P < 0.05).  Deletion from 274 
to 323 bp of proximal promoter eliminated glucocorticoid responsiveness, suggestive of a 
glucocorticoid response element (GRE).  Electrophoretic mobility shift assays (EMSAs) 
using a radiolabeled oligonucleotide spanning -290/-270 bp of proximal promoter 
revealed increased binding of nuclear extracts from αT3-1 cells treated with 100 nM 
dexamethasone compared to vehicle.  Mass spectrometry analysis of isolated proteins 
from a pull-down using a biotinylated oligonucleotide (-290/-270 bp) identified PARP-1 
as the binding component.  EMSAs with either GR or PARP-1 antibodies resulted in a 
supershift of the specific binding complex, whereas addition of both antibodies abolished 
the supershift.  Inhibition of p38 and ERK1/2 mitogen-activated protein kinase (MAPK) 
pathways decreased dexamethasone-induced promoter activity (P < 0.05), indicating their 
involvement in glucocorticoid stimulation of the promoter.  Thus, our working model for 
glucocorticoid responsiveness of the porcine GnRHR gene suggests that binding of 
glucocorticoid to its receptor (GR), triggers GR phosophorylation by p38 and ERK1/2 
MAPK pathways, resulting in the recruitment of PARP-1 by phosphorylated, ligand-
bound GR to a GRE located within -290/-270 bp of the porcine GnRHR promoter.
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CHAPTER I 
 
INTRODUCTION 
 
The decapeptide gonadotropin-releasing hormone (GnRH) is a key factor that 
mediates the function of the hypothalamic-pituitary-gonadal axis in mammals.  Generated 
by hypothalamic neurons, GnRH is released in an intermittent manner, traveling to 
gonadotropes in the anterior pituitary gland via the hypothalamo-hypophyseal portal 
system (Fink, 1988).  Gonadotropin-releasing hormone binds to high-affinity receptors on 
gonadotrope cells resulting in the biosynthesis and secretion of both follicle stimulating 
hormone (FSH) and luteinizing hormone (LH), which stimulate steroid synthesis and 
gametogenesis in the gonads (Clayton and Catt, 1981; Clarke et al., 1983; Mason et al., 
1986).  Upon binding to its receptor, GnRH regulates expression of at least 4 
gonadotropic genes including those encoding: the common α-glycoprotein subunit, the 
specific LHβ- and FSHβ-subunits that combine to produce LH or FSH (Hamernik and 
Nett, 1988; Gharib et al., 1990), and the GnRH receptor (GnRHR) itself (Sealfon and 
Millar, 1995).  Transcriptional regulation of GnRHR is mediated by GnRH via protein 
kinase A (PKA) and C (PKC) activation of multiple mitogen-activated protein kinase 
(MAPK) pathways including extracellular signal-regulated kinase (ERK), c-Jun N-
terminal kinase (JNK), p38 MAPK, and ERK5, also known as big MAPK1 (BMK1; 
Sundaresan et al., 1996; Roberson et al., 1999; Noar et al., 2000; Liu et al., 2003; Bonfil 
et al., 2004). Thus, the interaction between GnRH and its receptor represents a central 
point for regulation of reproductive function in mammals. 
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Many studies have examined responsiveness of the GnRHR gene to hormones 
including GnRH (White et al., 1999; Norwitz et al., 1999; Ellsworth et al., 2003; Liu et 
al., 2003), estradiol-17β (Gregg et al., 1990; Laws et al., 1990b; Wu et al., 1994; Duval et 
al., 2000), progesterone (Laws et al., 1990a; Cheng et al., 2001a), testosterone (Kaiser et 
al., 1993; Curtin et al., 2001; Zapatero-Caballero et al., 2003) activin (Fernandez-
Vazquez et al., 1996; Pernasetti et al., 2001; Norwitz et al., 2002), and inhibin (Braden et 
al., 1990; Gregg et al., 1991; Wu et al., 1994). Several reports indicated that GnRH 
regulates GnRHR numbers and mRNA levels in the pituitary gland from the rat (Pieper et 
al., 1982; Clayton, 1982; Kaiser et al., 1993; Bauer-Dantoin et al., 1995), sheep (Turzillo 
et al., 1994), and cow (Vizcarra et al., 1997). In contrast, others reported no change in 
amounts of GnRHR mRNA after GnRH treatment in the gonadotrope-derived αT3-1 cell 
line (Tsutsumi et al., 1993, 1995; Alarid and Mellon, 1995). Besides regulation of the 
level of GnRHR mRNA, GnRH can both up- and down-regulate receptor numbers in the 
pituitary (McArdle et al., 1987; Uemura et al., 1992; Bauer-Dantoin et al., 1993; Conn et 
al., 1995). Norwitz et al. (1999) determined two elements involved in GnRH 
responsiveness, sequence underlying responsiveness to GnRH-1 and 2 (SURG-1 and 
SURG-2, respectively) and Kam et al. (2005) reported that nuclear factor Y (NF-Y) and 
octamer transcription factor-1 (Oct-1) bind to the SURG-1 element to increase basal and 
GnRH-stimulated expression of the mouse GnRHR gene.  White et al. (1999) isolated an 
activation protein-1 (AP-1) element within SURG-2 that conferred GnRH responsiveness 
of the GnRHR promoter. Moreover, these investigators identified that GnRH regulation 
of the GnRHR gene was mediated via activation of an AP-1 element by PKC (White et 
al., 1999) and the JNK pathway (Ellsworth et al., 2003).  In addition, the GnRHR 
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activating sequence (GRAS), important to basal promoter activity, also mediated activin 
responsiveness of the mouse GnRHR gene (Duval et al., 1999).  The binding of Smad3 
and 4 proteins to GRAS (Duval et al., 2000) and AP-1 complexes to an overlapping AP-1 
element regulated activin responsiveness (Ellsworth et al., 2003).  Further studies 
demonstrated that binding of the LIM homeodomain proteins, LHX2 and 3, to a 
downstream activin regulatory element (DARE) is also necessary for activin 
responsiveness (Cherrington et al., 2005; Cherrington et al., 2006). 
Reproductive function is suppressed under various stress conditions including 
infection, malnutrition, restraint, strenuous exercise, and surgical trauma (Collu et al., 
1984; Rabin et al., 1988; Rivest and Rivier, 1995). Hormones that comprise components 
of the HPA axis, such as CRH, arginine vasopressin, ACTH, and glucocorticoids have all 
been shown to inhibit GnRH/gonadotropin secretion at the hypothalamic and/or pituitary 
levels. CRH inhibits GnRH release in hypophyseal portal blood (Rabin et al., 1988) or 
GnRH pulse generator activity (Williams et al., 1990). Arginine vasopressin and ACTH 
are also reported to inhibit LH secretion by decreasing responsiveness of the pituitary to 
GnRH as well as decreasing GnRH release (Dobson and Smith, 2000; Cates et al., 1999; 
Mann et al., 1985). 
Inhibitory effects of glucocorticoids on gonadotropin secretion have been well 
documented in a variety of species, ranging from rodents to ruminants and primates, 
including humans.  Chronic or acute glucocorticoid treatment is reported to suppress LH 
secretion in normal (nonstressed) animals or subjects (Baldwin, 1979; Saketos et al., 
1993; Breen et al., 2004).  Thus, exogenous glucocorticoids injected into normal subjects 
do inhibit LH secretion. The importance of the report by Matsuwaki et al. (2006) is that it 
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elucidated the role of endogenous glucocorticoids released in response to stimuli induced 
by stressors.  The investigators found that glucocorticoids are protective rather than 
inhibitory to LH secretion under stressful conditions.  Their findings imply that there may 
be substantial differences in the observed actions of exogenous glucocorticoids 
administered into normal (nonstressed) subjects and endogenous glucocorticoids released 
in stressed subjects.  Previous reports by the same authors showed that glucocorticoids 
counteract the suppressive effects of TNF-α, which mimics infectious stress, on both the 
pulsatile (Matsuwaki et al., 2003) and surge (Matsuwaki et al., 2004) secretion of LH in 
rats.  In support of their findings, two other reports demonstrated that endogenous 
glucocorticoids did not mediate endotoxin-induced inhibition of pulsatile LH secretion in 
rats (Watanobe and Habu, 2003) and sheep (Debus et al., 2002).  They show that 
lipopolysaccharide suppresses LH pulses even in adrenalectomized rats and in sheep 
treated with metyrapone, a glucocorticoid synthesis inhibitor. 
Glucocorticoids can also act at both the hypothalamus and anterior pituitary gland 
to regulate gonadotropin secretion (Brann and Mahesh, 1991; Tilbrook et al., 2000).  
Recent investigations into stress-related influences on reproductive function implicated 
glucocorticoids in the physiological regulation of GnRH and its receptors.  For example, 
glucocorticoids acted directly at the hypothalamus to suppress GnRH synthesis 
(Chandran et al., 1994) and reduced the activity of the GnRH pulse-generating center 
(Dubey and Plant, 1985).  Similarly, in the anterior pituitary gland, glucocorticoids 
decreased GnRH responsiveness of gonadotrope cells (Kamel and Kubajak, 1987; 
Baldwin et al., 1991).  In contrast to inhibition of GnRH secretion from the hypothalamus 
and reduced responsiveness of gonadotropes to GnRH, glucocorticoids also increased 
5 
GnRHR mRNA and protein levels.  In male rats, the glucocorticoid agonist, 
dexamethasone, acted directly on gonadotrope cells to modulate a GnRH-induced 
increase in GnRHR numbers, as well as gonadotropin gene expression and secretion 
(Rosen et al, 1991).  In addition, dexamethasone treatment increased endogenous GnRHR 
mRNA levels in the gonadotrope-derived LβT2 cell line (Turgeon et al., 1996) and 
activity of the murine GnRHR promoter in pituitary adenoma-derived GGH3 (Maya-
Núñez and Conn, 2003) and LβT2 (McGillivray et al., 2007) cells.  Maya-Núñez and 
Conn (2003) identified the glucocorticoid response element (GRE) as an AP-1 binding 
site located between 255 and 331 bp upstream of the transcriptional start site that bound 
the transcription factor, c-Jun, suggesting that ligand-bound glucocorticoid receptors 
interact directly or indirectly with c-Jun to regulate GnRHR transcription.  Our laboratory 
has isolated the porcine GnRHR gene promoter and identified elements conferring basal 
activity in αT3-1 cells.  The objectives of this study are to determine glucocorticoid 
responsiveness of the porcine GnRHR gene, to isolate the glucocorticoid response 
element(s) located within the porcine GnRHR promoter and to examine the molecular 
mechanisms underlying glucocorticoid stimulation of GnRHR gene expression in αT3-1 
cells. 
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CHAPTER II 
 
LITERATURE REVIEW 
 
Characterization of Gonadotropin-Releasing Hormone 
  
Function of Gonadotropin-releasing hormone 
Gonadotropin-releasing hormone (GnRH) is a hypothalamic decapeptide that 
plays a critical role in regulation of reproduction.  It was first isolated from mammalian 
hypothalami (Schally et al., 1971; Matsuo et al., 1971; Baba et al., 1971), and is 
important for normal mammalian sexual maturation as well as reproductive function and 
pregnancy (Bauer-Dantoin et al., 1993; Kaiser et al., 1997; Zapatero-Caballero et al., 
2003; Granger et al., 2004).  GnRH is secreted from hypothalamic neurons in a pulsatile 
manner every 30-120 minutes (Millar et al., 2004), travels through a portal system to the 
anterior pituitary gland, and stimulates one of five cell types, gonadotropes, in the 
anterior pituitary gland (Conn and Crowley, 1994; Carmel et al., 1976; Levine et al., 
1982).  GnRH binds to its cognate receptor on the plasma membrane of gonadotrope cells 
to stimulate the biosynthesis and release of the gonadotropins, luteinizing hormone (LH) 
and follicle stimulating hormone (FSH; Figure 2.1).  Upon binding to is receptor, GnRH 
upregulates at least gonadotropic genes including: the common α-glycoprotein subunit, 
specific LH and FSH β-subunits and the GnRHR itself (Gharib et al., 1990; Sealfon and 
Millar, 1995).  The common α-subunit then interacts with either LH or FSH β-subunits to 
produce LH and  
7 
 
 
Figure 2.1.  Diagram of GnRH action on a gonadotrope cell.  GnRH is secreted by 
neurons in the hypothalamus and acts on gonadotrope cells of the anterior pituitary gland.  
Binding of GnRH to its cognate receptor on the plasma membrane of the cell causes the 
upregulation of genes encoding the common glycoprotein hormone α-subunit and 
specific FSHβ- and LHβ-subunit genes, as well as the GnRHR itself. 
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FSH, respectively (Clarke et al., 1983).  Following synthesis and secretion of these 
gonadotropins, they act on the gonads to function in reproduction.  LH causes ovulation 
in the female and promotes testosterone production in the male (Velardo, 1960; Veyssiere 
et al., 1977).  FSH recruits follicle development in the female and stimulates 
spermatogenesis in the male (Velardo, 1960; Weissenberg et al., 1982).  In addition, 
gonadotropins induced the production of androgens, progesterone and estradiol-17β.  
These steroid hormones can negatively feedback at the level of the anterior pituitary and 
the hypothalamus to regulate GnRH and gonadotropin secretion (Nakai et al., 1978; 
McNeilly et al., 2003).  Therefore, the interaction between GnRH and its receptor 
represents a central point for regulation of reproductive function in mammals. 
 In addition to its role in regulating reproduction, GnRH can also have diverse 
functions in neuroendocrine, paracrine, autocrine and neurotransmitter/neuromodulatory 
roles.  Neuroendocrine functions have been shown in growth hormone release in certain 
fish species, paracrine roles in placenta and gonads, autocrine actions in GnRH neurons, 
immune cells, breast and prostatic cancer cells, and neurotransmitter/neuromodulatory 
roles in the central and peripheral nervous system (Emons and Schally, 1994; Sherwood, 
1987; Millar and King, 1987; Millar and King 1988; Jennes and Conn, 1994; Millar et al., 
2004; Millar, 2005; Kochman, 2012).  It has been reported that GnRH peptides may 
originally function in cellular communication in sexual reproduction of simple 
organisms. Later, they were recruited to nerve cells to translate external and internal 
signals into activation of reproduction, initially by acting directly on germ cells, and 
subsequently via pituitary gonadotrope activation (Millar, 2005; Millar et al., 1987; 
Hsueh and Schaeffer, 1985; Jennes and Conn, 1994) 
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Structure of Gonadotropin-Releasing Hormone 
 Mammalian GnRH was first isolated from the ovine, bovine and porcine 
hypothalamus (Kochman, 1966; Kochman 1969; Kochman and Domański, 1969), but its 
characterization and primary structure were not known until Andrew V. Schally and 
Roger Guillemin demonstrated them in 1971 (Matsuo et al., 1971; Burgus et al., 1972).  
During subsequent years of intensive studies, 30 structurally different forms of GnRH 
have been identified (Table 2.1).  In vertebrates, 15 structural variants of the GnRH 
molecule have been reported and 15 variants were found in invertebrates (Millar et al., 
2004; Roch et al., 2011).  
 The mammalian GnRH peptide consists of 10 amino acids which is pGlu-His-
Trp-Ser-Tyr-Leu-Arg-Pro-Gly-NH2 (Schally et al., 1971).  The N-terminal (pGlu-His-
Trp-Ser) and C-terminal (Pro-Gly-NH2) sequences have been highly conserved for 
approximately 600 million years of evolution (Millar et al., 2004; Millar, 2005), with the 
exception of two cases of conservative Tyr substitutions (Table 2.1).  These highly 
conservative features are critically important for receptor binding and activation and 
variations in positions 5, 7 and 8 are important for ligand selectivity (Millar et al., 2004; 
Kochman, 2012).  However, position 8 is the most variable amino acid and this variation 
suggests that virtually any residue is tolerated in the position.  Therefore, this residue may 
play an important function in ligand-selectivity of the different GnRH receptors (Millar, 
2005).  It has been reported that these conserved NH2- and COOH-terminal groups are 
closely apposed when mammalian GnRH binds its receptor, due to a β-II type turn 
involving residues 5-8 (Figure 2.2; Sealfon et al., 1997; Karten and Rivier, 1986).  This 
conformational change results from intramolecular interactions with side chain of Arg in   
10 
1  Mammal* 
2  Chicken I 
3  Guinea Pig 
4  Frog 
5  Seabream 
6  Salmon*** 
7  Medaka 
8  Catfish 
9  Whitefish 
10  Herring 
11  Dogfish 
12  Lamprey II 
13  Chicken II** 
 
14  Lamprey III 
15  Lamprey I 
 
16  Chelyosoma I 
17  Chelyosoma II 
18  Ciona I 
19  Ciona II 
20  Ciona III 
21  Ciona IV 
22  Ciona V 
23  Ciona VI 
24  Ciona VII 
pGlu  His   Trp    Ser 
pGlu His Trp  Ser 
pGlu Tyr Tyr  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu  His   Trp    Ser 
 
 
pGlu His Trp  Ser 
pGlu  His   Tyr    Ser 
 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu His Trp  Ser 
pGlu  His   Trp    Ser 
Tyr 
Tyr 
Tyr 
Tyr 
Tyr 
Tyr 
Phe 
His 
Tyr 
His 
His 
His 
His 
 
His 
Gly 
Gly 
Gly 
Gly 
Gly 
Gly 
Gly 
Gly 
Gly 
Gly 
Gly 
Gly 
Gly 
 
Gly 
Leu   Arg 
Leu    Gln 
 Val    Arg 
Leu    Trp 
Leu    Ser 
Trp     Leu 
Leu    Ser 
Leu    Asn 
Met    Asn 
Leu    Ser 
Trp     Leu 
Trp     Phe 
Trp    Tyr 
 
Trp    Lys 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
Pro   Gly NH 
2 
  Pro   Gly  NH2 
Leu   Glu    Trp    Lys 
 
Asp   Tyr    Phe   Lys 
Leu   Cys   His    Ala 
  Tyr    Ala     Leu    Ser 
  Leu   Ala    Leu   Ser 
  Asn   Gln    Leu   Thr 
  Tyr    Glu    Phe    Met 
  Tyr    Glu   Tyr     Met 
 Lys    Gly    Tyr      Ser 
  Asn   Lys   Leu     Ala 
    
 
TABLE 2.1  AMINO ACID SEQUENCES OF NATURALLY OCCURRING GnRH 
STRUCTURAL VARIANTS SPANNING APPROXIMATELY 500 MILLION YEAR 
OF EVOLUTION 
 
Amino acid sequence 
1        2        3 4 5 6 7 8         9         10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
1        2       3 4 5       6 7 8 9     10      11     12 
25  Octopus 
26  Sea Urchin 
27  Aplysia 
28  Limpet 
29  Marine worm 
30  Leech 
pGlu  Asn  Tyr   His 
pGlu  Val   His   His 
pGlu  Asn  Tyr   His 
pGlu  His   Tyr   His 
pGlu  Ala   Tyr   His 
pGlu   Ser   Ile    His 
 
Phe  Ser Asn 
Arg  Phe  Ser 
 Phe Ser  Asn 
 Phe Ser  Asn 
 Phe Ser  His 
Gly 
Gly 
Gly 
Gly 
Gly 
Trp  His  Pro 
Trp  Arg  Pro 
 Trp   Tyr   Ala 
Trp  Lys   Ser 
Trp  Phe Pro 
Gly   NH 
2 
Gly   NH 
2 
- NH 
2 
- NH 
2 
- NH 
2 
- NH 
2 
Phe Ser  Asn  Ser  Trp  Gln  Pro 
*   mammal - mammalian GnRH; mGnRH:GnRH I  
** chicken II - cGnRH II : GnRH II 
*** salmon GnRH - sGnRH : GnRH III 
† The encircled amino acid residues (on the left and on the right) show the conserved NH2- and              
   COOH-terminal residues that play important functional roles.  Non-conserved residues are  
   either unimportant or convey ligand selectivity for a particular GnRH receptor.  The GnRHs  
   are named according to the species in which they were first discovered, and they may be  
   represented in more than one species.  Adapted from Kochman (2012). 
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Figure 2.2.  Schematic presentation of mammalian GnRH in the folded conformation in 
which it is bound to the GnRH receptor.  The molecule is bent around the flexible glycine 
in position six.  Substitution with D-amino acids in this position stabilizes the folded 
conformation, increases binding affinity, and decreases metabolic clearance.  This feature 
is incorporated in all agonist and antagonist analogues.  The NH2 and COOH termini are 
involved in receptor binding.  The NH2 terminus alone is involved in receptor activation 
and substitutions in this region produce antagonists.  Adapted from Millar (2005) 
  
12 
position 8 (Milton et al., 1983; Guarnieri and Weinstein, 1996).  In addition, substitution 
of Arg caused a more extended form with a loss of a specific tertiary structure and a low 
binding affinity for its receptor (Maliekal et al., 1997).  These extended forms, however, 
showed high activity in non-mammalian GnRH receptors (Sealfon et al., 1997; Illing et 
al., 1999; Tensen et al., 1997), whereas they exhibited low activity at mammalian 
receptors (Flanagan et al., 1994; Fromme et al., 2001).   
 
Characterization of Gonadotropin-Releasing Hormone Receptor 
 
Amino Acid Sequences of Gonadotropin-Releasing Hormone Receptor 
 The amino acid sequence of the GnRH receptor (GnRHR) was established first 
for the mouse receptor cloned from the murine gonadotrope-derived cell line, αT3-1, 
utilizing a PCR-based homology cloning strategy (Windle et al., 1990; Sealfon et al., 
1990; Tsutsumi et al, 1992) and was subsequently confirmed using Xenopus oocyte and 
mammalian cell line expression cloning (Reinhart et al., 1992; Perrin et al., 1993).  This 
sequence provided the basis for cloning of additional homologous pituitary cDNAs in 
other mammalian species including the human (Kakar et al., 1992; Chi et al., 1993), rat 
(Eidne et al., 1992; Kaiser et al., 1992; Perrin et al., 1993), sheep (Brooks et al., 1993; 
Illing et al., 1993), cow (Kakar et al., 1993) and pig (Weesner and Matteri, 1994).  An 
alignment of the cloned GnRHR sequences is shown in Figure 2.3.  This sequence 
alignment shows more than 85% conserved homology overall and is nearly identical 
within the putative transmembrane domains (Sealfon et al., 1997; Cheng and Leung, 
2000).  Also, this alignment revealed that the cow, sheep, pig and human receptors have   
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Figure 2.3.  Sequence alignment of cloned GnRH receptors.  The putative transmembrane 
domains are indicated. m, Murine; r, rat; h, human; o, ovine; b, bovine; p, pig; cf, catfish. 
The consensus sequence reflects the mammalian sequences only. The junctions between 
exons in the murine and human receptors are indicated by **.  Adapted from Sealfon 
(1997). 
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one more amino acid compared to the mouse and rat receptors (327 amino acid residues),  
due to the absence of one residue in the second extracellular domain (Kochman, 2012; 
Cheng and Leung, 2000; Millar, 2005).  Unlike the mammalian receptors, non-
mammalian receptors have only 58 – 68% identity among each other and those with the 
greatest homology to mammalian pituitary receptors have at most 42 – 47% amino acid 
identity (Millar, 2005; Millar et al., 2004; Kochman, 2012). 
 
Structure of Gonadotropin-Releasing Hormone Receptor 
 The GnRHR is a member of the rhodopsin-like, G protein-coupled receptor 
(GPCR) family which contains seven transmembrane (TM) domains (Stojilkovic et al., 
1994; Sealfon et al., 1997; Cui et al., 2000).  The NH2-terminal group is followed by 
seven putative, α-helical TM domains connected by three extracellular loop and three 
intracellular loop domains (Figure 2.4; Kakar et al., 2002; Neill, 2002; Millar, 2005).  
The extracellular and superficial regions of the TMs are usually important for 
conformational change during receptor activation following ligand binding, whereas the 
intracellular domains are involved in interacting with G-proteins and other proteins 
associated with intracellular transduction (Millar, 2005; Kakar et al., 2002). 
 Unlike other members of the GPCR family, GnRHRs do not have an intracellular 
C-terminal domain which is required for desensitization and internalization of many 
GPCRs (Conn et al., 1995; Kakar et al., 1992; Tsutsumi et al., 1992; Stojilkovic et al., 
1994).  In most GPCRs, the C-terminus contains several phosphorylation sites that are 
involved in ligand binding and play an important role in receptor desensitization 
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Figure 2.4.  Two-dimensional representation of the human GnRH receptor showing 
amino acids conserved between cloned vertebrate GnRH receptors (yellow) and 
conservative substitutions (blue). Putative ligand binding sites and residues important 
in receptor configuration, activation and G-protein coupling are indicated. 
Glycosylation, phosphorylation and disulphide bridge sites are also shown.  Adapted 
from Millar (2005). 
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and internalization (Leeb-Lundberg et al., 1987; Sibley et al., 1987).  For example, 
removal of the C-terminal domain decreased the rate of internalization of thyrotropin-
releasing hormone receptor (Nussenzveig et al., 1993), diminished agonist-induced 
internalization of gastrin-releasing peptide (Benya et al., 1993), lost internalization and 
endocytosis of the angiotensin type I receptor (Hunyady et al., 1994; Thomas et al., 1995) 
and delayed desensitization and sequestration of the LH, α-1B-adrenergic and β-
adrenergic receptors  (Lattion et al., 1994; Strader et al., 1987; Zhu et al., 1993).  In αT3 
cells, GnRH stimulated the accumulation of [
3
H]-thymidine for at least 90 min (Davidson 
et al., 1994b) and increased the levels of inositol triphosphate (IP3) for at least 5 min 
(Anderson et al., 1995; McArdle et al., 1996; Merelli et al., 1992), suggesting that the 
GnRHR does not undergo rapid desensitization in αT3 cells due to the lack of C-terminal 
tail and the phosphorylation sites necessary for agonist-dependent desensitization (Kakar 
et al., 2004). 
 In addition, the GnRHR contains five potential phosphorylation sites in the 
intracellular loops.  Willars et al. (1998) reported that these sites are not involved in 
agonist-dependent phosphorylation, suggesting the phosphorylation sites present in the 
intracellular loops may not be important for desensitization of the receptor.  The GnRHR 
also possesses potential protein kinase C (PKC), phospholipase C (PLC) and cAMP-
dependent protein kinase A (PKA) phosphorylation sites in the intracellular loops.  One 
PKC phosphorylation site is located in the first intracellular loop, whereas three potential 
PLC sites and one potential PKA site are present in the third intracellular loop (Kakar et 
al., 2004).  Cassina et al. (1999) demonstrated that both PKC and PKA phosphorylated 
synthetic peptides for the three intracellular loops in vitro.  Consistent with this, they  
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showed that treatment of rat pituitary cell cultures in combination with phorbol 12-
myristate 13-acetate (PMA) and cholera toxin reduced LH secretion, whereas individual 
treatment of PMA and cholera toxin had no effect on LH secretion, suggesting that more 
than one signaling pathway is required to induce GnRHR desensitization.  Mutation of all 
the potential PKC phosphorylation sites (Thr
238
, Ser
253
, and Thr
264
) in the third 
intracellular loop to Ala abolished the binding affinity of the receptor and reduced IP3 
production (Lin et al., 1998; Ulloa-Aguirre et al., 1998), whereas mutation of only Ser
253
 
and Thr
264
 to Ala did not alter ligand binding or IP3 production.  However, ligand binding 
affinity (Ulloa-Aguirre et al., 1998) and receptor-mediated signal transduction (Lin et al., 
1998) were decreased when the C-terminal domain of the third intracellular loop was 
deleted.  Collectively, this evidence indicated that residues in the C-terminal domain of 
the third intracellular loop, including the PKC phosphorylation sites, are important for the 
structural integrity, expression, and signal transduction of the GnRHR. 
 
Tissue Expression of Gonadotropin-Releasing Hormone Receptor 
 In general, GnRHRs are expressed only on the plasma membrane of gonadotropes 
to control reproductive function (Clayton and Catt, 1981; Childs and Unabia, 1997).  
Rodents are an exception with in that GnRHRs are also present in the gonads (Kakar et 
al., 1992).  However, other tissues bind [
125
I]-labled GnRH agonists, suggestive of 
GnRHR expression.  Early studies described that the binding affinities of GnRH to 
extrapituitary tissues measured using radioreceptor assays were significantly lower than 
those of the receptor on gonadotropes of the anterior pituitary (Bramley et al., 1986; 
Eidne et al., 1985; Emons et al., 1989; Vincze et al., 1991).  These include specific nuclei 
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in the central nervous system (Jennes et al., 1997), human placenta (Wolfahrt et al., 
1998), somatotropes (Leibow et al., 1991), and various tumors of the pituitary and 
pancreas (Emons et al., 1998).  In addition, the discovery of more potent GnRH 
analogues allowed the identification of high affinity binding sites in various hormone-
responsive human tumors (breast and prostate) as well as cells derived from breast, 
prostate, liver, uterine endometrium, and ovarian tumors (Chen et al., 1992; Emons et al., 
1993; Emons and Schally, 1994; Irmer et al., 1995; Segal-Abramson et al., 1992; Yano et 
al., 1994). 
 In the ovary, granulosa-luteal cells express GnRHR mRNAs and mRNA levels 
increase with follicular growth and development (Peng et al., 1994).  GnRHR binding has 
been demonstrated in luteinized granulosa cells, late antral follicles and developing 
corpora lutea, but not in primordial, early antral and preovulatory follicles (Brus et al., 
1997; Choi et al., 2006).  This stage-specific expression of GnRHR in human granulosa 
and luteal cells suggests a role for GnRH in the regulation of ovarian physiology (Cheung 
and Wong, 2008).   GnRHR protein and mRNA have also been found in human ovarian 
tumors, ovarian cancer cell lines and their tissue of origin, ovarian surface epithelium 
(Choi et al., 2001; Emons et al., 1989).  Interestingly, GnRHR levels in ovarian 
carcinomas are increased in advanced (stages III and IV) compared to early (stages I and 
II) stages (Chien et al., 2004). 
 In addition to the ovary, GnRHR has been found in testicular germ cells of the rat 
and mouse (Bull et al., 2000) and receptor binding studies with GnRH agonists revealed 
the presence of GnRHR on Leydig cells of human testicular tissue (Clayton et al., 1980; 
Lefebvre et al., 1980).  Later, the mRNA sequence of these testicular receptors was 
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determined to be identical to those on gonadotrope cells of the anterior pituitary (Botte et 
al., 1998).  However, GnRHR mRNA levels were decreased by direct binding of GnRH 
analogs to testicular GnRHRs (Botte et al., 1999), suggesting that specific GnRHRs on 
Leydig cells were important in the physiological regulation of testicular function and the 
anti-fertility effects of GnRH agonists within the testis (Lefebvre et al., 1980). 
 The human placenta also had specific binding sites for GnRH that interacted with 
GnRH agonists and antagonists (Iwashita et al., 1986) and were localized to 
cytotrophoblast and syncytiotrophoblast cell layers of the placenta (Casan et al., 1999; 
Boyle et al., 1998).  This placenta GnRHR was structurally and biochemically identical to 
pituitary GnRHRs, although GnRH binding affinity was lower (Escher et al., 1988; 
Bramley et al., 1992).  During pregnancy, GnRHRs are dynamically dispersed (Cheng et 
al., 2001) and temporal expression of GnRHRs in placental cells has been observed at 
different weeks of gestation, along with chorionic gonadotropin secretion level (Lin et al., 
1995).  
 Although GnRHRs have been isolated in breast tissue (Casan et al., 1998), its 
expression was questioned due to a small sample size (Kottler et al., 1997).  However, 
others immunolocalized the GnRHR to the cytoplasm of human breast cancer cell lines 
and tumor biopsy specimens (Kottler et al., 1997; Moriya et al., 2001; Eidne et al., 1987). 
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Signal Transduction Mechanisms of the Mammalian GnRH Receptor 
 
Receptor Activation 
 GnRH activation of signaling pathways is initiated by a change in receptor 
conformation and propagated by intracellular pathways within the cell (Kenakin, 1993).  
For GPCRs, the active conformation is related to a ternary complex consisting of 
hormone, receptor and G-protein (De Lean et al., 1980).  This ternary complex develops 
an initial binding step common to both agonists and antagonists, followed by a transition 
step, exclusive to agonists, which leads to formation of the ternary complex.  The model 
also allows for spontaneous formation of a receptor-G-protein complex, which has a 
higher affinity for agonists and is stabilized via binding of agonists.  When GTP binds to 
the G-protein, the receptor returns to the low affinity conformation and the complex 
dissociates (De Lean et al., 1980).  There are a number of different GnRHR active 
conformations that are selective for GnRH analogues and intracellular signaling pathways 
(Millar and Pawson, 2004). 
 
G-Protein Coupling 
 GPCRs transmit their signals primarily via GTP-binding proteins (G-proteins), 
which are heterotrimeric proteins composed of an α subunit (Gα) that binds guanine 
nucleotides, and a dimer that consists of a β and γ subunit (Gβγ).  Upon stimulation, Gα 
dissociates from the Gβγ dimer rendering to its active GTP-bound form to influence 
effector molecules.  The βγ dimer remains attached to the plasma membrane and can 
initiate several signaling events (Kraus et al., 2001). G-proteins can be classified into the 
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four following groups: Gαs, Gαi, Gαq/11, and Gα12/13.  Gαs mainly activates adenylate 
cyclase, which induces the production of high levels of the second messenger cAMP.  
Unlike Gαs, the Gαi protein has inhibitory effects on adenylate cyclase (Birnbaumer, 
1992).  Gαq/11 principally exerts its action by activating membrane-associated 
phospholipase C (Hsieh and Martin, 1992), whereas Gα12/13 primarily operates by 
stimulation of protein tyrosine kinases (PTKs; Jiang et al., 1998). 
The nature of G-protein coupled signaling initiated by the GnRHR depends 
largely on the cellular context (Figure 2.5).  For example, it has been demonstrated that 
the human GnRHR couples to Gαq/11 in heterologous Chinese hamster ovary-K1 and 
COS-7 cells (Grosse et al., 2000) but to Gαs in the placenta (Cheng et al., 2000).  In 
contrast, others reported that the receptor couples selectively to Gαi in some reproductive 
tract tumors and  cell lines derived from them (Emons et al., 1998; Grundker et al., 2001; 
Limonta et al., 1999; Imai et al, 1996).  Interestingly, the rodent GnRHR couples to 
multiple G-proteins in LβT2 (Liu et al., 2002), GGH3 (Stanislaus et al., 1998), and GT1-7 
(Krsmanovic et al., 2003) cells.  In GT1-7 neurons, elevated GnRH analogue 
concentrations induced a ligand-dependent switch of G-protein coupling from Gαs to Gαi,  
which inhibits episodic GnRH release (Krsmanovic et al., 2003).  Such negative feedback 
action serves as an autocrine mechanism for pulsatile GnRH secretion that is essential for 
the maintenance of normal gonadotropin release profiles and gonadal function (Cheng 
and Leung, 2005). 
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Figure 2.5.  Signal transduction cascades activated by GnRH within gonadotrope cells.  
Upon binding of GnRH to GnRHR, intracellular signaling pathways are triggered via 
PKA and/or PKC.  Following activation of PKC, a variety of MAPK pathways including 
JNK, ERK, or p38 MAPK can be activated. 
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Activation of Protein Kinase A or Protein Kinase C  
 Protein Kinase A.  Regulation of the GnRHR by GnRH occurs via two major 
signal transduction pathways, activation of protein kinase A (PKA) or protein kinase C 
(PKC).  In the PKA pathway, GnRHR is coupled to the Gαs protein (Figure 2.5).  Upon 
binding of GnRH to its receptor, the receptor is activated by a conformational change 
allowing dissociation of the Gαs protein from Gβ and Gγ protein subunits. Gαs 
consequently activates adenylate cyclase, which converts adenosine triphosphate (ATP) 
to cAMP (Figure 2.5).  Following production of increased amounts of cAMP, cAMP 
activates PKA (Figure 2.5), resulting in phosphorylation of a variety of other downstream 
signaling cascade proteins within the cell (Naor et al., 2000; Millar et al., 2004).  
In rat pituitary cell cultures, GnRH stimulated cAMP production (Hawes et al., 
1993).  Furthermore, GnRH agonist-induced release of cAMP occurred in 
somatolactotropes over-expressing the rat GnRHR (GH3; Kuphal et al, 1994), 
baculovirus-insect cells (sf9; Delahaye et al. 1997), monkey kidney COS-7 cells over-
expressing the human GnRHR (Arora et al., 1998) and Chinese hamster ovary (CHO; 
Nelson et al., 1999) cells.  In αT3-1 cells, treatment with 8-bromo-cAMP and forskolin 
stimulated GnRHR mRNA levels (Sadie et al., 2003).  Additional studies indicated that 
GnRH utilizes the PKA signaling pathway to stimulate its target cells.  For instance, 
treatment of both pituitary and αT3-1 cells with pituitary adenylate cyclase-activating 
polypeptide (PACAP) resulted in increased α-subunit mRNA levels (Tsujii et al., 1995).  
However, White et al. (1999) reported that forskolin treatment completely blocked 
GnRH-stimulated GnRHR promoter activity.  Similarly, Norwitz et al. (1999) found that 
the major signaling pathway in αT3-1cells that confers GnRH responsiveness of the 
24 
mouse and human GnRHR gene promoters is the PKC, and not the PKA pathway.  These 
results indicates that, although GnRHR may not be directly regulated via the PKA 
signaling pathway, the receptor can be regulated in response to other signaling molecules 
that activate the PKA pathway. 
 
Protein Kinase C.  In αT3-1 cells, binding of GnRH to its heptahelical receptor 
leads to the stimulation of Gαq/11 protein (Shah and Milligan, 1994) and activation of 
phospholipase Cβ1 (PLCβ1; Naor, 1990) followed by enhanced phosphoinositide 
turnover to inositol 1,4,5-triphosphate (IP3), production of diacylglycerol (DAG), and 
activation of various PKC subspecies (Harries et al., 1997).  Pituitary cells particularly 
express PKCδ and PKCε, but also atypical PKCs, which are DAG- and Ca2+-independent 
(Harries et al., 1997).  Generation of IP3 leads to an initial rapid rise in intracellular Ca
2+
 
concentration resulting from release of intracellular Ca
2+
 stores.  DAG leads to activation 
of PKC isozymes and contributes to a more sustained rise in intracellular Ca
2+
 through L-
type voltage gated channels (Benard et al., 2001).   
Ca
2+
 is an important intracellular messenger that regulates diverse physiological 
processes.   For example, treatment of pituitary cells with the Ca
2+
 ionophore ionomycin 
resulted in a significant stimulation of GnRH secretion (Stojilkovic et al., 1994; 
Stojilkovic et al., 1995; Trueta et al., 1999).  GnRH induces immediate intracellular Ca
2+
 
mobilization followed by extracellular Ca
2+
 influx. These GnRH-induced Ca
2+
 
oscillations occur through mobilization of two distinct calcium pools (Stojilkovic et al., 
1994; Iida et al., 1991).  Extracellular Ca
2+
 enters the cell through voltage-gated calcium 
channels in the plasma membrane, while IP3 releases Ca
2+
 from intracellular stores.  The 
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release of Ca
2+
 from intracellular stores is an important trigger for secretion in many 
cells.  In the case of GnRH, both intracellular and extracellular Ca
2+
 were shown to be 
involved in the secretion of LH and FSH (Stojilkovic et al., 1994; Naor, 1990; Stojilkovic 
et al., 1995).  However, the IP3-released calcium seems to be critical for gonadotropin 
secretion, whereas Ca
2+
 influx through the plasma membrane is mainly required for the 
renewal of internal stores (Tse et al., 1997).  Therefore, activation of PKC and increased 
Ca
2+
 concentrations are among the important events that mediate GnRH action in 
pituitary cells.  Furthermore, these events are prerequisite for activation of mitogen-
activated protein kinase (MAPK) activity, in particular the extracellular signal-regulated 
kinase (ERK) pathway (Mulvaney and Roberson, 2000). 
  
Activation of Mitogen-Activated Protein Kinase 
 The MAPK pathways are highly conserved signal transduction cascades that 
mediate cellular responses to a large variety of environmental stimuli (Bliss et al., 2010).  
In mammals, there are 4 predominant MAPK pathways: the ERK, jun-N-terminal kinase 
(JNK), p38, and ERK5/Big MAP kinase (ERK5/BMK) pathways.  Activation of the 
pathway begins with phosphorylation of an upstream MAP kinase-kinase kinase 
(MAPKKK), which phosphorylates and activates an intermediate level MAP kinase 
kinase (MAPKK).  The MAPKK in turn activates and the terminal MAP kinase (MAPK).  
In addition to these core kinases, numerous scaffolding and adaptor proteins play 
important roles in this pathway (Morrison and Davis, 2003).  Activated MAPKs 
phosphorylate numerous substrates throughout the cell including those involved with 
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transcriptional machinery, chromatic components, cytoskeletal structures, and other 
downstream enzymes (Pearson et al., 2001; Yoon and Seger, 2006). 
 In pituitary-derived cells, GnRH activated all four MAPK cascades to various 
extents by a PKC- and tyrosine-kinase dependent mechanism (Naor et al., 2000).  In αT3-
1 cells, GnRH activated the JNK pathway by approximately 20-fold (Levi et al., 1998).  
Activation of JNK was transient, peaking at 30 min and declining thereafter.  Similarly, 
the ERKs were also activated (~12-fold), ERK phosphorylation was detected 2 min after 
GnRH treatment, peaked at 7 min, and decreased to basal levels within 60 min (Benard et 
al., 2001).  On the other hand, the remaining two MAPKs, p38 MAPK and BMK1, were 
only slightly activated (2 to 3-fold) in a transient manner, peaking 30 min after 
stimulation (Roberson et al., 1999).  However, the mechanism underlying MAPK 
activation is significantly varied among systems.  For example, in GGH3 cells, ERK 
activity is mediated by both PKA and PKC (Han and Conn, 1999).  In Caov-3 cells, 
GnRHR signals either through Gα or the dissociated Gβγ dimer, whereas in LβT2 cells, 
JNK activation by GnRH is not dependent on PKC (Yokoi et al., 2000).  
 Activation of ERKs by GnRH has been widely studied (Sim et al., 1993; Mitchell 
et al., 1994; Roberson et al., 1995).  Alterations in GnRH pulse pattern affect the 
responsiveness of ERKs to GnRH (Haisenleder et al., 1998).  Continuous exposure of 
αT3-1 cells to GnRH stimulated short-term (2 h) ERK activity, whereas pulsatile GnRH 
stimulated ERK activity for at least 8 h.  Thus, GnRH pulses are required to maintain and 
prolong activation of ERKs.  In similar manner, TPA (a PKC activator) caused a 2 h 
stimulation of ERKs, whereas EGF induced a much shorter effect (Reiss et al., 1997).  
The similar time-course obtained with GnRH and TPA indicated that PKC may be 
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involved in the activation of ERKs by GnRH in αT3-1 cells.  PKC depletion results in 
marked inhibition of the GnRH response (Reiss et al., 1997) and the PKC inhibitor 
GF109203X abolishes GnRH-induced ERK activation (Benard et al., 2001).  Therefore, 
ERK activation by GnRH in pituitary cells is mainly PKC-dependent (Kraus et al., 2001).  
Activation of ERKs by GnRH in αT3-1 cells involves two distinct signaling pathways 
that converge at the level of Raf1 (Benard et al., 2001).  The main pathway involves 
direct activation of Raf1 by PKC, whereas the second, supportive pathway involves 
activation of Ras in a c-Src- and dynamin-dependent manner (Benard et al., 2001).  
Pretreatment with the PKC inhibitor GF109203X abolished GnRH-induced ERK 
activation, whereas the PTK inhibitor, genistein, and the c-Src inhibitor, PP1, only 
partially inhibited by ~40%, respectively.  In addition, co-overexpression with the C-
terminal Src kinase (CSK), which acts as a dominant-negative interfering mutant of c-
Src, and with the dominant negative form of Ras had a partial inhibitory effect by 35% on 
the GnRH to ERK  pathway (Benard et al., 2001).  Dynamin appears important for the 
GnRH to ERK pathway because its dominant-negative form inhibited activation of Ras in 
a PKC-independent manner. 
 Ca
2+
 is a critical mediator of the induction of gonadotropin secretion by GnRH.  
Removal of Ca
2+
 markedly reduced ERK activation by GnRH (Reiss et al., 1997) and 
calcium influx through voltage-gated calcium channels (VGCCs) is absolutely required 
for activation of ERKs by GnRH in both αT3-1 and primary cultured pituitary cells 
(Mulvaney and Roberson, 2000).  Treatment of ells with the PKC inhibitor staurosporine 
blocks the GnRH-induced VGCC signal, indicating that Ca
2+
 operates downstream of 
PKC in the pathway that leads to ERK activation.  Similar dependency on PKC and Ca
2+
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was also demonstrated in LβT2 cells (Yokoi et al., 2000), indicating that ERK activation 
by GnRH in pituitary cells is strongly dependent upon DAG-sensitive PKC isozymes and 
requires Ca
2+
. 
 The JNK signaling cascade is also the main MAPK pathway involved in GnRH 
signaling in αT3-1 cells.  JNKs ate activated 20 to 50-fold by GnRH and by TPA in αT3-
1 cells (Levi et al., 1998).  Time-course of JNK activation in response to GnRH is slower 
than that of ERK activation, indicating that regulation of JNK activation by GnRH is 
different from that of ERK.  Levi et al. (1998) also showed that activation of JNKs is 
both PKC- and PTK-dependent.  However, PTK inhibitors completely abolished GnRH-
induced JNK activation, but depletion of PKC or the use of PKC inhibitors prevented 
only ~70% of GnRH-JNK signals, indicating the existence of a PKC-independent 
signaling component.  They found that GnRH as well as TPA also increased the activity 
of c-Src.  Coexpression of CSK and constitutively active forms of c-Src, together with 
JNK1, confirmed the involvement of c-Src downstream of PKC in the GnRH-JNK1 
pathway.  They further demonstrated that c-Src together with the small GTPase CDC42 
(and possibly Rac) and MEKK1 are the main mediators of the GnRH-JNK1 pathway.  
Collectively, GnRH stimulates JNKs activity by a pathway that includes sequential 
activation of PKC, c-Src, CDC42 (Rac), and MEKK1.   
 MAPKs play a role in the regulation of gene expression in various systems, either 
by activating nuclear transcription factors directly or by phosphorylating downstream 
cytoplasmic protein kinases.  For example, ERK phosphorylates the ternary complex 
factor Elk1, a member of the Ets family of transcription factors (Marais et al., 1993).  
Elk1 has been shown to bind to the GnRH-responsive element located within the α-
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subunit gene promoter region, and GnRH increases promoter activity in αT3-1 cells 
(Roberson et al., 1995).  In αT3-1 cells, ERK is translocated into the nucleus within 20-
30 min of GnRH stimulation and this nuclear translocation supports a role for ERKs in 
transcriptional regulation of gonadotropin subunit genes (Kraus et al., 2001; Roberson et 
al., 1995; Haisenleder et al., 1998).  Moreover, the MEK inhibitor PD098059 was shown 
to block GnRH-stimulated mRNA accumulation of the α-subunit and FSHβ in GnRH via 
ERK-, PKA, and Ca
2+
- dependent pathways (Lin and Conn, 1999).   
 JNKs were also shown in many systems to translocate into the nucleus upon 
stimulation to phosphorylate and activate transcription factors such as c-Jun, ATF2, Elk1, 
and p53.  Levi et al. (1998) reported that the delayed response of JNKs observed in their 
experiments may indicate that JNKs are involved in a later stage of transcriptional 
regulation.  Activation of JNKs and ERKs provides a route for activation of c-jun and c-
fos, respectively to form the jun-fos dimer that might activate the activator protein-1 (AP-
1) responsive element present in both LHβ and FSHβ promoter (Hirai et al., 1990).  
Strahl et al., (1998) also showed that GnRH induces FSHβ gene expression via activation 
of the AP-1 element.  Although GnRH induction and basal control of the α-subunit gene 
appear to occur through the ERK pathway, induction of the LHβ gene is dependent on 
JNKs, suggesting the differential stimulation of transcription of LH subunit genes by 
GnRH (Kraus et al., 2001).  Yokoi et al., (2000) has shown that the JNK cascade is 
necessary to elicit the LHβ promoter in a c-Jun-dependent mechanism in LβT2 cells.  In 
addition, it was reported that the common α-subunit gene is regulated by c-Jun and ATF2 
at the cAMP-responsive element (CRE) site and by Elk1 at the Ets site of the pituitary 
glycoprotein hormone basal element (PGBE) domain (Roberson et al., 1999; Heckert et 
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al., 1996).  Therefore, it is likely that the MAPK cascades play a role in the expression of 
α- and β-subunits of gonadotropin genes. 
 
Transcriptional Regulation of GnRHR by Hormone 
 
Basal Expression of GnRHR Gene 
The 5′ flanking regions of GnRH I genes have been characterized in the mouse 
(Albarracin et al., 1994), rat (Reinhart et al., 1997), human (Fan et al., 1995; Kakar, 
1997) and sheep (Campion et al., 1996).  The mouse and rat promoters share > 80% 
homology over 1.9 kb.  However, the rat promoter shares 55% homology with the human 
promoter over 2.2 kb and 63% homology with the sheep promoter over 0.9 kb (Pincas et 
al., 1998). There are several highly homologous regions within the proximal 500 bp of 
the mouse, rat, human and sheep promoters (Pincas et al., 1998).  The mouse GnRHR I 
proximal promoter was the first to be isolated and characterized (Albarracin et al., 1994). 
The major transcription start site in primary pituitary tissue and αT3-1 cells is located at 
−62 (all numbering is relative to the translation start site) and is not associated with a 
consensus TATA box (Sadie et al., 2003; Albarracin et al., 1994).  In addition to this site, 
Clay et al. (1995) identified other pituitary transcription start sites at −90 and −200 bp in 
αT3-1 cells.  Regulation of the basal activity of the mouse promoter in αT3-1 cells is 
conferred by a tripartite basal enhancer, which includes binding sites for steroidogenic 
factor-1 (SF-1) at −244/−236, activator protein-1 (AP-1) at −336/−330, and GnRHR-
activating sequence (GRAS) at −391/−380 (Duval et al., 1997).  The pan-pituitary 
homeobox transcription factor Pitx-1 has been shown to interact with AP-1 in intact 
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LβT2 cells, indicating that this interaction might be important for GnRHR I gonadotroph-
specific, basal promoter activity (Jeong et al., 2004).  In addition, the promoter region 
around −360, shown to bind LHX3 homeodomain protein in vitro and in intact cells, was 
recently demonstrated to be important for mouse GnRHR I basal promoter activity in 
αT3-1 cells (McGillivray et al., 2005).   
In the rat proximal GnRHR I promoter, the transcription start site in αT3-1 cells 
was initially found to be 103 bp upstream from the start codon, with a putative TATA 
box 23 bp upstream from the transcription start site (Reinhart et al., 1997).  Later, five 
major transcription start sites in αT3-1 cells were identified, including four of them are 
clustered around −103, and one is located at −30, along with several minor start sites 
(Pincas et al., 1998).  Maximal cell specific expression of the rat GnRHR I is achieved by 
multiple regulatory domains within 1260 bp of 5′ flanking region.  A distal GnRHR-
specific enhancer (GnSE), located between −1135 and −753, contains binding sites for 
GATA-related and LIM homeodomain-related factors, and facilitates gonadotroph-
specific expression through functional interaction with an SF-1 site at − 245 (Pincas et al., 
1998; Pincas et al., 2001).  AP-1 site in the rat promoter is also involved in basal 
promoter activity, but has no influence on the GnSE function (Hapgood et al., 2005).  
The function of the proximal rat promoter and the GnSE is supported by results obtained 
in transgenic mice, showing that the proximal 1.1-kb rat GnRHR I promoter is sufficient 
to drive gonadotroph-specific expression. Furthermore, 3.3 kb of the rat promoter was 
found to drive cell-specific expression of the transgene in gonadotrophs and certain areas 
of the brain (Granger et al., 2004). 
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The 5′ flanking regions of the human and sheep genes are much more complex 
than that of the mouse and rat genes, with the presence of multiple transcription start sites 
and CAP sites (Campion et al., 1996; Ngan et al., 2000).  Although the sheep proximal 5′ 
flanking region is structurally similar to the mouse promoter, it has greater sequence 
homology to the human promoter (Campion et al., 1996).  In contrast to the single start 
site identified in mouse pituitary tissue (Sadie et al, 2003), 18 transcription start sites 
have been identified for the human GnRHR I gene in human pituitary tissue (Kakar, 
1997). These start sites are located between −1748 and −577 and are well dispersed 
among several TATA and CCAAT boxes.  The proximal 173 bp of the human 5′ flanking 
region is critical for basal promoter activity in αT3-1 cells (Ngan et al., 1999).  However, 
upon limited availability of human gonadotropic cell lines, the results in mouse cell lines 
may not be physiologically relevant (Hapgood et al., 2005).  The mouse, rat and human 
promoters all contain several SF-1 sites, with at least one site in each promoter occurring 
in the 5′ untranslated region (UTR).  For the human promoter, this site is located at 
−140/−134 and is primarily responsible for mediating high cell-specific expression in 
αT3-1 cells (Ngan et al., 1999), whereas for the mouse and rat, it is situated at −15/−7 in 
both species and has no function for the cell-specific expression (Sadie et al., 2003).  An 
upstream Oct-1 binding at −1718 is also required for basal activity of the human 
promoter in αT3-1 cells (Cheng et al., 2001).   
The transcription factor Oct-1 appears to regulate basal GnRHR I gene expression 
both positively and negatively, depending on the species and cell-type (Hapgood et al., 
2005).  For example, Oct-1 is required for basal expression of the human GnRHR I gene 
in several cell types, including placental, ovarian and gonadotroph cell lines, via an Oct-1 
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binding site at −1718 (Cheng et al., 2001).  On the other hand, in placental JEG-3 cells, 
ovarian OVCAR-3 cells and αT3-1 cells, Oct-1 acts as a potent repressor of the human 
GnRHR I promoter via a negative regulatory element (NRE) at position −1017 (Cheng et 
al., 2002).  Oct-1 is also involved in basal and GnRH-stimulated activity of the mouse 
GnRHR I promoter in αT3-1 cells via the SURG-1 (Sequence Underlying 
Responsiveness to GnRH) element (Kam et al., 2005). 
The mouse CRE has been found to be essential for basal promoter activity in 
some pituitary cell lines, such as LβT2 cells (Hapgood et al., 2005) and GGH3 
somatolactotroph cells (Maya-Nunez and Conn, 1999), but the rat CRE does not appear 
to be involved in basal promoter activity in αT3-1 cells (Pincas et al., 2001).  A CRE at 
position −1650 is required for placenta-specific expression of the human GnRHR I gene 
(Cheng et al., 2001). These findings demonstrate that CREs contribute to a cell- and/or 
species-specific expression of GnRHR I gene. 
 
Transcriptional Regulation of GnRHR by GnRH 
Homologous regulation of the GnRHR is a physiologically relevant mechanism 
for increasing pituitary sensitivity to GnRH during ovulation (White et al., 1999).  
Therefore, GnRH activation of GnRHR is a potent stimulus for increased expression of 
multiple genes including the gene encoding the GnRHR itself.  GnRH regulates the 
GnRHR with short-term exposure to hormone leading to an increase in receptor 
expression, whereas prolonged exposure leads to receptor down-regulation (Norwitz et 
al., 1999).  It is widely accepted that pulsatile GnRH stimulation is essential for 
appropriate GnRHR expression levels, at the same time avoiding receptor down-
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regulation due to continuous hormonal stimulation (Liu et al., 2003).  The effects of 
GnRH on GnRHR protein and/or mRNA levels in primary pituitary cultures and cell 
lines suggest a direct mechanism of GnRH on pituitary cells, with a combination of both 
transcriptional and post-transcriptional mechanisms regulating GnRHR expression levels 
(Hapgood et al., 2005).  For example, in attempts to mimic the situation in vivo, rat 
pituitary cultures were stimulated with GnRH in a pulsatile fashion, resulting in increased 
GnRHR mRNA levels (Kaiser et al., 1993) via MAPK and possibly also cAMP/PKA 
pathways (Haisenleder et al., 1998; Borgeat et al., 1972).  Different pulse frequencies 
were found to have different effects on GnRHR mRNA, with higher pulse frequencies 
causing maximal stimulation (Kaiser et al., 1997). 
The expression levels of mouse GnRHR promoter–reporter constructs transfected 
into αT3-1 cells increase in response to 100 nM GnRH after 4–6 h of continuous 
stimulation (Norwitz et al., 1999).  This GnRH responsiveness was identified to two 
regions, designated SURG-1 and SURG-2 (Norwitz et al., 1999).  SURG-1 contains 
binding sites for nuclear factor Y (NF-Y) and Oct-1, and it was shown by chromatin 
immunoprecipitation assays that GnRH increased binding of these factors to SURG-1 in 
intact cells (Kam et al., 2005).  GnRH responsiveness via SURG-2 appears to be 
mediated by PKC-induced activation of JNK which increases expression, activity and 
binding of AP-1 proteins to SURG-2 (Ellsworth et al., 2003).  SURG-1 and SURG-2 can 
respond to GnRH independently, but the AP-1 element is critical for conferring maximal 
GnRH responsiveness (Norwitz et al., 1999).  These findings are consistent with the 
results obtained in transgenic mice (Ellsworth et al., 2003).  However, in the mouse 
promoter, responsiveness to GnRH also involves binding of Smad and AP-1 factors to 
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another composite element called GRAS, which occurs further upstream at position 
− 391/−380 (Norwitz et al., 2002; Norwitz et al., 2002).  
In LβT2 cells, endogenous GnRHR mRNA and protein levels are up-regulated 
upon long-term pulsatile GnRH stimulation (Turgeon et al., 1996; Bedecarrats et al., 
2003), whereas long-term continuous stimulation down-regulates receptor levels 
(Bedecarrates et al., 2003).  However, both continuous and pulsatile stimulation induced 
only a small increase in the activity of a transfected 1.2 kb mouse GnRHR promoter 
(Bedecarrates et al., 2003).  Stanislaus et al. (1994) studied the regulation of mouse 
GnRHR promoter activity in the GGH3 cell line, which was engineered by stably 
transfecting GH3 rat somatolactotroph cells with rat GnRHR cDNA.  They found several 
intracellular signaling pathways involved in mediating the up-regulation of the mouse 
GnRHR promoter activity by GnRH in these cells, such as PKA (Lin and Conn, 1998), 
PKC and the Ca
2+
 signaling pathway (Lin and Conn, 1999).  In contrast to the results in 
αT3-1 cells, the AP-1 site does not appear to be involved (White et al., 1999; Norwitz et 
al., 1999; Maya-Nunez and Conn, 2003).  However, functional studies indicate a role for 
the PKA pathway and cAMP response elements (CREs) in regulating GnRHR promoter 
activity in mouse, rat and human.  These results may indicate differences in GnRHR G-
protein coupling between the cell lines.  All of these promoters contain functional CREs 
and are up-regulated by activators of the PKA pathway in αT3-1 cells (Sadie et al., 2003; 
Pincas et al., 2001; Cheng and Leung, 2001).  Other factors likely to be involved in 
mediating PKA responses are CREB (Tsutsumi et al., 1995) for the rat and SF-1 (Sadie et 
al., 2003; Pincas et al., 2001) for the rat and mouse promoters. 
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Transcriptional Regulation of GnRHR by Steroid Hormones 
Estradiol.  Studies in rat, sheep and cow conclude that estradiol increases the 
level of GnRHR mRNA and protein in pituitary consistent with a requirement for a 
strong, prolonged LH surge for ovulation during the preovulatory phase of the 
reproductive cycle (Crowder and Nett, 1984; Savoy-Moore et al., 1980).  Experiments in 
ovariectomized transgenic mice harboring a sheep GnRHR promoter-reporter construct, 
as well as experiments in sheep primary pituitary cells, suggest that transcription is the 
predominant mechanism of estradiol up-regulation of GnRHR numbers in the pituitary 
(Duval et al., 2000; Wu et al., 1994; Laws et al., 1990; Gregg et al., 1990).  However, 
estradiol stimulation of αT3-1 cells was found to down-regulate GnRHR numbers 
(McArdle et al., 1992), whereas estradiol stimulation of LβT2 cells had little effect on 
endogenous GnRHR gene expression (Turgeon et al., 1996; McArdle et al., 1992).  These 
conflicting results highlight the apparent discrepancies that may occur when using 
transformed cell lines compared to primary cells that contain mixed cell populations.  In 
addition, Turzillo et al. (1994) reported that the GnRHR I mRNA levels increase before 
an increase in circulating concentration of estradiol and this result leads to postulate that a 
decrease in progesterone, rather than an increase in estradiol, is required for up-regulation 
of GnRHR I numbers.   
Progesterone.  In most mammals, high levels of progesterone correlate with 
reduced GnRHR I protein levels in pituitary and reduced pituitary responsiveness to 
GnRH I during the luteal phase of the menstrual cycle and during pregnancy (Crowder 
and Nett, 1984; Batra and Miller, 1985; Sakurai et al., 1997).  In sheep pituitary cells, 
GnRHR numbers were dramatically down-regulated by progesterone within 48 h (Wu et 
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al., 1994; Laws et al., 1990), consistent with a direct effect of progesterone on the 
pituitary.  Progesterone was also able to prevent estradiol- and inhibin-induced increases 
in GnRHR I mRNA levels in these cells.  Recent results with the human GnRHR I 
promoter in αT3-1 cells showed that progesterone administration and overexpression of 
progesterone receptor (PR) isoforms inhibited GnRHR I promoter activity (Cheng et al., 
2001), suggesting that, at least for the human promoter, repression by progesterone 
occurs via direct transcriptional effects on the GnRHR I promoter in gonadotrophs 
(Hapgood et al., 2005).  Furthermore, this negative effect was shown to occur via a 
glucocorticoid response element (GRE)/progesterone response element (PRE) at 
−535/−521, which has 75% homology to a consensus progesterone response element, and 
to which PR isoforms were shown to bind in vitro (Cheng et al., 2001).  In the same 
study, a half-PRE binding site was shown to be located at −402/−397. However, this site 
did not show a function in the progesterone-mediated transcriptional effects.  
Interestingly, another putative GRE/PRE is located further upstream (Fan et al., 1995), 
but its function remains unknown. 
 
Testosterone.  In male rats, pituitary GnRHR I mRNA levels appear to be 
repressed by testosterone because a negative correlation exists between mRNA levels and 
testosterone concentrations in serum (Kaiser et al., 1993; Zapatero-Caballero et al., 
2003).  GnRHR I numbers in primary pituitary cultures from male rats decreased after 
treatment with α-dihydrotestosterone (Tibolt and Childs, 1985), consistent with in vivo 
results and suggesting direct actions of α-dihydrotestosterone on the pituitary.  In 
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contrast, α-dihydrotestosterone up-regulated GnRHR I mRNA levels in LβT2 cells 
(Curtin et al., 2001). 
 
Transcriptional Regulation of GnRHR by Growth Factors and Other Regulators 
Activin and inhibin, both members of the transforming growth factor-β family of 
proteins, are produced by primary gonadotrophs (Roberts et al., 1992), αT3-1 
(Fernandez-Vazquez et al., 1996) and LβT2 cells (Pernasetti et al., 2001), and exert 
autocrine/paracrine effects on pituitary cells.  Activin-A stimulates the rate of synthesis 
of new GnRHRs in rat pituitary cell cultures (Braden and Conn, 1992), and decreases 
receptor numbers in sheep pituitary cultures (Gregg et al., 1991).  Inhibin was found to 
prevent the stimulation of receptor synthesis by GnRH I in rat pituitary cultures (Braden 
et al., 1990), but increases GnRHR I mRNA levels (Wu et al., 1994) and receptor 
numbers (Gregg et al., 1991) in sheep pituitary cultures.  In αT3-1 and LβT2 cells, long-
term stimulation with activin-A up-regulates endogenous GnRHR I mRNA synthesis and 
mouse GnRHR I promoter-reporter activity (Fernandez-Vazquez et al., 1996; Pernasetti 
et al., 2001), and pretreatment of αT3-1 cells with activin enhances the response of the 
mouse GnRHR I promoter to GnRH I (Norwitz et al., 2002).  Follistatin blocks the 
activin-mediated stimulation at both mRNA and promoter level.  In addition, follistatin 
decreases the basal activity of the mouse GnRHR I promoter in αT3-1 and LβT2 cells, 
indicating that endogenous activin maintains basal GnRHR I expression levels in these 
cells (Norwitz et al., 2002; Fenandez-Vazquez et al., 1996; Penasetti et al., 2001).  
Activin responsiveness of the mouse GnRHR I promoter was mapped to the GRAS 
element (Duval et al., 1999) described earlier, together with a region immediately 
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downstream from GRAS, termed DARE (down-stream activin regulatory element) 
(Cherrington et al., 2005).  The mouse GRAS element is a composite regulatory element 
for which the functional activity in αT3-1 cells depends on the proper organization and 
assembly of a multiprotein complex, which includes Smad, AP-1 and FoxL2 proteins 
(Ellsworth et al., 2003).  Basal GnRHR I promoter activity, as well as responsiveness to 
GnRH I and to activin require binding of Smad factors to the Smad binding element, as 
well as binding of AP-1 to a novel AP-1 element contained within GRAS (Norwitz et al., 
2002; Norwitz et al., 2002).  The LIM-homeodomain protein LHX2 was shown to bind 
the DARE sequence in vitro (Cherrington et al., 2005).  It has been postulated that activin 
responsiveness requires a specific configuration of multiple transcription factors on these 
distinct elements, to form a complex activin-responsive ‘enhanceosome’ (Cherrington et 
al., 2005).  Interestingly, the sequence of the corresponding GRAS element in the rat 
Pincas et al., 2001; Cherrington et al., 2005), suggesting that the rat DARE sequence is 
nonfunctional for activin responsiveness. 
Pituitary adenylate cyclase activating polypeptide (PACAP) is a hypothalamic 
peptide hormone that modulates pulsatile GnRH I release from the hypothalamus and 
responsiveness to GnRH I, as well as regulates gonadotropin subunit expression 
(Rawlings and Hezareh, 1996).  The mouse, rat and human GnRHR I promoters have all 
been shown to be regulated by PACAP in αT3-1 cells (Sadie et al., 2003; Pincas et al., 
2001; Cheng and Leung, 2001).  For the rat and human promoters, this has been shown to 
involve PKA (Pincas et al., 2001; Cheng and Leung, 2001).  Two promoter elements, 
designated PARE (PACAP response element) I and PARE II, are required for the 
PACAP response of the rat GnRHR I promoter.  PARE I includes the SF-1 binding site at 
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position −245/−237, along with binding sites for additional factors, whereas PARE II 
contains an imperfect cAMP response element (CRE) at position −110/−103 that can 
bind CREB (Pincas et al., 2001).  Both the SF-1 site and the imperfect CRE are 
conserved in relative position in the mouse GnRHR I promoter, raising the possibility 
that a similar mechanism could be responsible for the PACAP response of the mouse 
promoter. 
 
Stress and Reproduction 
  
Glucocorticoids (GC) and Glucocorticoid Receptor (GR) 
 GCs are steroid hormones that are synthesized and secreted from the adrenal 
cortex in response to stress via hypothalamic-pituitary-adrenal (HPA) axis.  HPA 
activation leads to the release of the neurohormone corticotrophin-releasing hormone 
(CRH).  The release of CRH causes an increase in the adrenocorticotrpic releasing 
hormone (ACTH) and cortisol levels resulting in the activation of the sympathetic 
nervous system causing an increase in glucose levels, heart rate and blood pressure 
(Smoak and Cidlowski, 2004).  General functions of GC are the regulation of glucose, 
fat, and protein metabolism.  GC are also important for the protection of the body against 
stress by regulating glucose metabolism and blood pressure (De Bosscher et al., 2001).  
In addition, they have an important role in the dynamic modulation of the inflammatory 
and immune responses.  The action of GC is caused by the interruption of pro-
inflammatory, cytokine-mediated signaling pathways and by causing apoptosis in certain 
cells of the immune system.  In several immune and inflammatory diseases, which 
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include rheumatoid arthritis, inflammatory bowel disease and asthma, exogenous 
synthetic GC are prescribed.  The biological actions of GC as anti-inflammatory agents 
exert their actions via the interaction of this hormone with its cognate receptor, which is a 
member of the nuclear receptor superfamily of proteins (Smoak and Cidlowski, 2004). 
GCs act through the glucocorticoid receptor (GR), a member of the superfamily 
of nuclear receptors (Griekspoor et al., 2007).  In the absence of ligand, GR resides in the 
cytosol as part of a chaperone-containing multi-protein complex, which maintains a high 
affinity for the ligand.  Upon hormone binding, GR translocates to the nucleus, where it 
acts as a transcription factor (TF).  The GR subunits homodimerize and bind DNA at 
glucocorticoid response elements (GREs) in the vicinity of target genes (Schoneveld et 
al., 2004).  GRE-bound GR recruits multiple transcriptional co-activator complexes, 
which stimulate transcription (Jenkins et al., 2001; Schaaf and Cidlowski, 2002).  These 
properties of GR are reflected by its modular structure (Fig).  The central domain 
contains two zinc fingers providing a dimerization interface as well as the DNA binding 
domain (DBD; Beato et al., 1995).  The C-terminal ligand-binding domain (LBD) is 
responsible for high affinity binding of GCs. The LBD overlaps with the activation 
domain AF2 (activation domain 2), which is exposed after a conformational change 
induced by ligand binding (Kumar and Thompson, 2003).  The exposed AF2 mediates 
the interaction with co-activators.  The N-terminal part of the receptor contains AF1, a 
ligand-independent activation function, required for transcriptional enhancement through 
the recruitment of co-activators, and association with basal transcription factors (Kumar 
and Thompson, 2003).  The trans-activation function of GR cannot solely account for the 
numerous physiologic effects of GCs.  GR also controls many cellular processes by 
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influencing multiple pathways in a trans-activation independent manner.  In particular, 
GR modulates, positively or negatively, the trans-activation function of other TFs.  The 
modulation may also function the other way around, GR transcriptional activity being 
potentiated or inhibited by another TF.  The regulation can be either indirect, resulting 
from an interference with upstream signaling pathways regulating the activation of TFs, 
or can result from a direct mutual regulation of GR and the other TF at the promoter of 
the target gene (Kassel and Herrlich, 2007). 
 
Regulation of Transcription Activity via GR Binding to DNA 
Glucocorticoids action is mediated via glucocorticoid receptor (GR), nuclear 
receptor that regulates physiological events through activation or repression of target 
genes involved in inflammation, gluconeogenesis and adipocyte differentiation.  In the 
absence of glucocorticoid ligand, GRs exist in the cytoplasm in a multimeric complex 
composed of heat shock proteins (HSPs), including hsp90, hsp56 and hsp40, p23, Src, 
and others (Dittmar et al., 1997; Hawle et al., 2006).  Ligand binding induces a 
conformational change in GR that leads to its dissociation from the multimeric complex, 
resulting in its dimerization and then rapid translocation into the nucleus and can elicit 
changes in gene expression (Croxtall et al., 2000; Ford et al., 1997 Glass and Rosenfeld, 
2000).  Translocated ligand-bound GRs, then, induce transcriptional regulation through 
several different ways. 
 
Direct activation via DNA Binding.  GR can bind DNA directly to regulate 
target gene expression through glucocorticoid response element (GRE), which is specific 
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DNA sequences, recognizing activated GRs.  If the GRE is in close proximity to the 
TATA-box, GR can recruit key components of the basal transcriptional machinery to the 
TATA-box, such as Transcription Factor IID (Ford et al., 1997), and thus directly 
promote gene activation. If the GRE is located at a distance of the TATA element, GR 
can associate with coactivators that function as bridges to promote the recruitment of the 
basal transcriptional machinery (Rosenfeld and Glass, 2001; Tronche et al., 2004).  
Furthermore, GR can also recruit chromatin-remodeling coactivators that alter the 
nucleosomal structure of the DNA and create a more favorable environment for gene 
expression.  Examples of genes positively regulated by GREs include tyrosine 
aminotransferase, alanine aminotransferase, and phosphoenolpyruvate carboxykinase, all 
involved in liver gluconeogenesis (Tronche et al., 2004). 
 
Indirect Activation via Protein-Protein Interaction.  GR can regulate gene 
activity independent of DNA binding via protein-protein interactions with other 
transcription factors.  Example of this mechanism is GR and Signal Transduction and 
Transcription proteins (STATs) interaction (Schindler, 1999; Zhang et al., 1997).  STATs 
are transcription factors involved in the Janus kinase (JAK) signaling pathway.  
Activation of JAK signaling results in the phosphorylation and dimerization of STATs, 
leading to their translocation into the nucleus and subsequent interaction with their 
response elements in the DNA.  In this case, STAT-5 physically interacts with GR. 
STAT-5 is directly associated with the DNA, while GR is recruited to the chromatin 
without direct interaction with the DNA. The GR-STAT-5 association leads to activation 
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of several genes, most notably IGF-1 in the liver that is required for postnatal growth 
(Zhang et al., 1997). 
 
nGRE Mechanism.  Direct DNA binding by GR can also lead to repression of 
genes by interactions with negative GREs (nGREs).  nGREs are similar to GREs and 
almost always are located in close proximity to DNA-binding sites for other transcription 
factors necessary for gene expression.  The osteocalcin gene promoter, for instance, 
contains an nGRE that overlaps with its TATA box, and GR association with this site 
prevents access from the basal transcriptional machinery (Meyer et al., 1997).  For 
example, the human FasL gene contains an nGRE adjacent to a nuclear factor κ B 
(NFκB) site (Novac et al., 2006).  GR-nGRE association in this site prevents NFκB 
binding and induces gene silencing (Ghosh and Karin, 2002).  Pro-opiomelanocortin 
(POMC), Corticotropin-releasing hormone (CRH), prolactin and neuronal serotonin 
receptor are down-regulated by this interaction. 
 
Indirect Repression via Protein-Protein Interaction.  most of the genes 
repressed by GR occur via protein-protein independent of DNA binding by the receptor.  
This signaling mechanism includes NFκB, activator protein-1 (AP-1), and Smad3. NFκB 
is a ubiquitous homo/heterodimer transcription factor most widely known for its role in 
inflammation.  The p50/p65 heterodimer is the most common combination involved in 
transcriptional processes (McKay and Cidlowski, 1998).  GR can physically bind to p65 
and repress the NFκB-mediated transcription.  For example, the interaction of GR with 
p65 can result in the sequestering of the NFκB complex, thereby preventing NFκB from 
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reaching its DNA-binding site (Almawi and Melemedjian, 2002).  GR can also interact 
with DNA-bound NFκB to inhibit the recruitment of the transcriptional machinery.  GR 
can also suppress NFκB transactivation by interfering with the cellular machinery 
necessary for gene activation (Nissen and Yamamoto, 2000).  Classical gene targets of 
NFκB that are repressed by GR include many pro-inflammatory cytokines and their 
receptors, such as tumor necrosis factor α (TNFα), interleukin-1β, and granulocyte 
monocyte colony stimulation factor.  Similar to NFκB, GR can bind and repress the 
transcriptional activity of AP-1 (Shaulian and Karin, 2002; Schule et al., 1990).  AP-1 is 
a homo/heterodimer transcription factor composed of Fos family or Jun family members.  
GR physically interacts with AP-1 and inhibits AP-1-mediated gene activation by 
employing similar mechanisms to the NFκB.  Genes repressed by GR in an AP-1-
dependent manner include collagenase, stromelysin, and other matrix metalloproteinases.  
In addition to NFκB and AP-1, GR physically interacts with Smad3 and greatly reduces 
the transcriptional activity of Smad3, which is phosphorylated by activated tumor growth 
factor β (TGFβ) receptor (Song et al., 1999; Li et al., 2003).  TGFβ-Smad signaling is 
important for cell differentiation, extracellular matrix production, as well as immune and 
inflammatory responses. 
 
The HPA-HPG Link 
 Many studies have been performed to link the HPA axis to the HPG axis.  
Recently, it was found that when rodents and non-human primates were treated with 
CRH, an immediate decrease in pulsatile GnRH and LH release (Smoak and Cidlowski, 
2004; Xia et al., 1996; Feng et al., 1991).  In humans, when the HPA axis is activated by 
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stress or by psychological disturbances, it results to an inhibition of the HPG axis.  If 
stress is severe enough, then it can lead to suppression of the normal menstrual cycle, 
which is referred to as functional hypothalamic amenorrhea and can lead to infertility 
when fully established (Reifenstein, 1946).  The final neuroendocrine events resulted in 
the suppression of the normal cycle is a decrease in the GnRH pulse generator resulting 
in a decrease in the hypothalamic GnRH activity and GnRHR number, leading to a 
decrease in the LH pulse frequency and eventually causing deficiencies in the normal 
menstrual cycle (Ferin, 1999).  CRH may not be the only HPA neurohormone involved in 
the stress response.  There is good evidence in the human and in animals that vasopressin 
of paraventricular origin is colocalized with CRH in perikarya and secretory granules and 
coreleased in stress (Mouri et al., 1993; Battaglia et al., 1997).  Vasopressin is known to 
act synergistically with CRH as an ACTH secretagogue (Rivier et al., 1984).   
 Experiments using μ-opiate receptor antagonist indicate that an increased 
endogenous opioid activity may somehow also account for the decreased pulsatility of the 
GnRH pulse generator in patients with functional hypothalamic chronic anovulation 
(Ferin, 1999).  For example, studies have shown that the administration of naloxone or 
naltrexone acutely restores normal LH pulse frequency, at least in a subgroup of these 
patients (Khoury et al., 1987).  In animals, the acute inhibitory action of CRH on pulsatile 
LH release is also clearly prevented by naloxone or by an antiserum to β-endorphin 
(Rivest et al., 1993; Gindoff and Ferin, 1987; Petraglia et al., 1986).  These human and 
animal studies suggest that increased endogenous opioid activity reflects enhanced 
central CRH release and mediates the endocrine actions of CRH on the HPG axis and 
support the existence of a HPA-HPG link (Ferin, 1999). 
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 Although the classical HPA-HPG link implies that activation of HPA will cause a 
decline in gonadotropin secretion, recent studies suggest that a reverse outcome is 
possible under a defined endocrine condition (Ferin, 1999).  For example, activation of 
HPA by IL-1 or endotoxin in the monkey during the midlate follicular phase (but not the 
early follicular phase or the luteal phase) results in an acute release of LH (Xiao et al. 
1996).  This observation evidently contrasts with the inhibitory effect of the cytokine on 
pulsatile LH secretion in the absence of estradiol (Feng et al., 1991).  A release of LH 
after HPA activation can also be produced in the ovariectomized monkey replaced with 
mid- to late follicular phase estradiol levels (Xiao et al., 1994).  This study indicates that 
the factor that is probably responsible for this acute stimulatory effect of HPA on LH 
release may be progesterone, as this effect is readily prevented by the administration of a 
progesterone antagonist (Xiao et al., 1994).  Xiao et al. (1994) have speculated that in 
stress, the small but significant increase in adrenal progesterone that occurs in response to 
HPA activation synergizes with circulating estradiol to enhance LH secretion.  This 
hypothesis was supported by the observation that the increase in LH is prevented by the 
administration of a CRH antagonist, demonstrating that HPA activation is required for 
this effect to occur (Xiao et al., 1994). 
 
Transcriptional Regulation of GnRHR by Glucocorticoid 
It is well documented that chronic or prolonged stress results in inhibition of 
gonadotropin secretion and inhibition of reproduction in mammals, whereas the effects of 
acute stress are less clear and can even stimulate reproduction (Tilbrook et al., 2000).  
Although the mechanisms whereby stress regulates reproduction in mammals are not well 
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defined, there is evidence that glucocorticoids play an important role in modulating 
pituitary responsive to GnRH I, as part of a feedback mechanism from adrenal to 
pituitary (Tilbrook et al., 2000; Breen and Karsch, 2004).  Further evidence for direct 
actions of glucocorticoids on pituitary is provided by findings that cortisol inhibits 
GnRH-induced LH release from bovine and porcine primary pituitary cells 
(Padmanabhan et al., 1983; Li, 1994).  One mechanism whereby glucocorticoids may 
regulate GnRH responsiveness in pituitary may be via modulating GnRHR levels.  Rosen 
et al. (1991) showed that glucocorticoids augmented GnRH I-induced increase in GnRHR 
I numbers in castrated testosterone-replaced male rats.  However, earlier studies in rats 
did not show a change in GnRHR I levels after treatment with corticosterone (Tibolt and 
Childs, 1985; Suter et al., 1988).  In sheep, administration of cortisol led to a decrease in 
GnRHR protein, but did not reduce GnRHR I mRNA levels (Daley et al., 1999).  These 
experiments suggest that varying effects of glucocorticoids on GnRHR I levels may 
depend on species, the cellular milieu, and the dose, type and duration of glucocorticoid 
administration.  However, a direct positive transcriptional effect of glucocorticoids on the 
mouse GnRHR I promoter has been established.  Glucocorticoids increased endogenous 
GnRHR I mRNA levels in LβT2 cells, whereas pretreatment with GnRH I further 
augmented this increase (Turgeon et al., 1996).  Glucocorticoids can also directly up-
regulate activity of the mouse GnRHR I promoter in GGH3 cells (Maya-Nunez and Conn, 
2003).  Although the tested 1.2 kb of 5′ flank of the mouse gene does not contain a 
classical GRE, the glucocorticoid-responsive region of the mouse GnRHR I promoter 
was mapped to the AP-1 site at −336 in GGH3 cells (Maya-Nunez and Conn, 2003).  The 
results from this study suggest that liganded glucocorticoid receptor interacts directly or 
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indirectly with AP-1 proteins, such as c-Jun, to increase GnRHR I transcription (Maya-
Nunez and Conn, 2003). 
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CHAPTER III 
 
MATERIALS AND METHODS 
 
Materials 
 Dexamethasone and mifepristone (RU486) were from Sigma (St. Louis, MO) and 
Org 31710 was a generous gift from N.V. Organon (Oss, Netherlands).  The antibody 
specific for PARP-1 (catalog no. 614301) was purchased from BioLegend (San Diego, 
CA), whereas the GR antibody (catalog no. sc-1004X) and normal rabbit IgG (catalog no. 
sc-2027) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  For 
experiments using EMSA, DNA probe (-290/-270; sense sequence 5’-
TTGTGAAAACCAGGCCATCTG-3’ and antisense sequence 5’-
CAGATGGCCTGGTTTTCACAA-3’) and competitive oligonucleotides containing 
consensus binding sites for specific transcription factors were synthesized by Integrated 
DNA Technologies (IDT, Coralville, IA). Biotinylated DNA probe 
(5’biotin/TTGTGAAAACCAGGCCATCTG-3’) was also synthesized by IDT for 
biotinylated DNA-pull down assays. 
 
Plasmid Preparation 
A reporter vector containing 5118 bp of porcine GnRHR promoter (-5118pGL3) 
was constructed by PCR amplification of the 5’ flanking region of the GnRHR gene from 
genomic DNA preparations of pigs representing a white crossbred line.  The PCR product 
was subsequently subcloned into pBluescript SK- (Stratagene, La Jolla, CA).  Promoter 
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inserts were ligated into a reporter vector containing the cDNA encoding luciferase 
(pGL3, Promega Corp., Madison, WI) at the SacI/EcoRV location of the multiple cloning 
site.  Deletion constructs were made by progressively removing 5’ flanking sequence 
(approximately 500 bp) via restriction enzyme digests and subsequent intramolecular 
ligation of the remaining vector backbone.  Construction of the 100-bp deletion reporter 
vectors was achieved by amplifying the specified region of the promoter by PCR with a 
Taq DNA polymerase containing 3’ to 5’ exonuclease activity (Bioline, Springfield, NJ).  
Next, the fragments were subcloned into pBluescript SK- or pCR-Blunt II (Invitrogen, 
Carlsbad, CA), and then finally placed into pGL3. 
 
Gel Extraction.  Appropriate plasmid fragments were extracted from agarose 
gels with the Qiaex II Agarose Gel Extraction Kit (Qiagen, Inc.).  Excised gel slices were 
weighed and buffer QX1 was added, followed by the addition of QIAEX II reagent.  Gel 
slices were incubated at 55°C for 10 min and vortexed every 2 min.  Samples were  
centrifuged using a Biofuge Pico (Kendro Lab Products) at 16,000 x g for 1 min and 
resulting pellets were washed with 500 μl of buffer QX1, followed by 2 washes (500 μl 
each) with buffer PE.  The pellet was allowed to air dry before it was resuspended in 20 
μl of tris-chloride (Tris-Cl; pH 8.5) and incubated at 55°C for 5 min.  Samples were then 
centrifuged at 16,000 x g for 1 min and the supernatant was collected. Another 20 μl Tris-
Cl (pH 8.5) was added to the pellet, with the incubation and centrifugation process 
repeated.  Plasmid fragments were then quantitated using A260 and A280 values 
determined with a Pharmacia GeneQuant spectrophotometer (Pfizer, New York, NY) and 
allowed to ligate at 15°C overnight. 
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Transformation.  For replication purposes, plasmids were transformed into 
RbCl competent DH5α cells (Invitrogen Life Technologies Corp.).  The plasmid ligation 
reaction (5 μl) was added to 50 μl of DH5α cells, gently mixed, and incubated on ice for 
30 minutes.  Cells were then heated to 42°C for 30 seconds, followed by a two minute 
incubation on ice.   The addition of 200 μl of SOB media (2% tryptone, 0.5% yeast 
extract,  8.55  mM  sodium  chloride,  250  mM  potassium  chloride,  2  M  magnesium 
chloride) preceded a one hour incubation shaking at 37°C.  Depending on the plasmid, 
100-200 μl of cells were plated on petri dishes containing LB media (Sigma Chemical 
Co., St. Louis, MO) with the addition of ampicillin and incubated inverted overnight at 
37°C. 
 
 DNA Extraction 
Alkaline Lysis Mini Plasmid Preparation.  Plasmid DNA was isolated from 
RbCl competent DH5α cells (Invitrogen Life Technologies Corp.) for plasmid 
screening purposes.   Two ml of LB media (Sigma Chemical Co.) and 2 μl of 
ampicillin were inoculated with a single colony of DH5α cells containing an ampicillin 
resistant plasmid and allowed to grow, shaking overnight at 37°C.  Cells were pelleted 
via centrifugation at 16,000 x g for one minute with a Biofuge Pico microcentrifuge 
(Kendro Lab Products). Following removal of the supernatant, cell pellets were 
resuspended in 100 μl of GTE (100  mM  glycine,  500  mM  
ethylenediaminetetraacetic  acid  [EDTA],  1  M  tris)  and incubated at room 
temperature for five minutes.   Sodium hydroxide/sodium dodecyl sulfate (200 μl; 
NaOH/SDS solution) was added to each sample.  Next, the sample was mixed gently 
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and allowed to incubate on ice for five minutes.  Samples were incubated another five 
minutes following the addition of 150 μl of potassium acetate (5M) and vortexed for 
two seconds.  Following centrifugation at 16,000 x g, the supernatant was placed in a 
clean 1.5-ml microcentrifuge tube, 800 μl of 100% ethanol was added, and tubes were 
incubated for two minutes at room temperature.  Samples were centrifuged at 16,000 x 
g for five minutes, the ethanol was removed, and the pellet was washed with 100 μl 
of 70% ethanol.  Following another five minutes of centrifugation at 16,000 x g, the  
pellet  was  allowed  to  dry  at  room  temperature  and  resuspended  in  1X  tris- 
ethylenediaminetetraacetic acid (TE, pH 8.0).   RNase A (0.5 μl) was added and each 
sample was incubated at 37°C or 30 minutes.   All newly constructed plasmids were 
screened via endonuclease restriction digestion prior to use. 
 
Plasmid Purification.  Following alkaline lysis mini preparation and appropriate 
screening with restriction enzymes, 100 ml of LB (with 150 μl ampicillin) was inoculated 
with remaining broth culture from the alkaline lysis preparation and grown, shaking 
overnight at 37°C.  Cells  were  isolated  from  the  resulting  broth  culture  by  4°C 
centrifugation at 6,000 x g for 15 minutes using a Sorvall RC2-B centrifuge (Du Pont Co., 
Newton, CT).  Preparation of plasmids for transfection was performed through using the 
Plasmid Purification Midi Kit (Qiagen Inc.).  Cell pellets were resuspended in 4 ml of 
buffer P1 and incubated for five minutes at room temperature, after the addition of 4 ml 
of lysis buffer P2.  Following incubation, 4 ml of precipitation buffer P3 was added to 
each of the samples, and they were incubated on ice for 15 minutes.  Samples were 
subjected to 4°C centrifugation at 20,000 x g for 30 minutes using a Sorvall RC2-B 
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centrifuge (Du Pont Co.) prior to being applied to a resin column.  All columns were 
equilibrated with buffer QBT before application of the cell lysate.  Columns were 
washed twice with 10 ml of buffer QC and plasmid DNA was eluted from the column 
with the addition of 5 ml of buffer QF.   Plasmid DNA was precipitated by adding 3.5 ml 
of isopropanol, followed by centrifugation at 4°C, spinning at 15,000 x g for 30 minutes 
using a Sorvall RC2-B centrifuge.  Pellets were washed with 2 ml of 70% ethanol and 
centrifuged at 4°C for 10 minutes at 15,000 x g in a Sorvall RC2-B centrifuge (Du Pont 
Co.).  After pellets had been allowed to air dry, they were resuspended in 250 μl of 
Millipore water.  All purified plasmids were quantitated through the  use  of  a  Lambda  
EZ  150  spectrophotometer  (Perkin  Elmer,  Boston,  MA)  and screened with restriction 
endonucleases prior to their use in transient transfection assays. 
 
Cell Culture 
αT3-1 (Dr. Pam Mellon, Salk Institute, La Jolla, CA) cells were maintained at 37 
C in a humidified 5% CO2 in air atmosphere.  The αT3-1 cells were cultured in high-
glucose DMEM (Mediatech, Herndon, VA) supplemented with 5% fetal bovine serum 
(FBS), 5% horse serum, 2 mM glutamine, 100 U/ml penicillin, and 100 µg/ml 
streptomycin sulfate (Gibco, Grand Island, NY).  Cultures of αT3-1 cells were 
maintained on 150-mm cell culture plates (Corning Inc., Corning, NY) in 20 ml of media.  
 
Transient Transfections 
Day 1.  Transient transfections were performed using a liposome-mediated 
protocol.   On Day 1, αT3-1 cells, typically at 70% confluency, were trypsinized and 
55 
plated for transfection.  The cells were washed with 10 ml of 1X phosphate-buffered 
saline (PBS) twice following aspiration of media.  Cells were trypsinized by adding 3 ml 
of 1X trypsin-EDTA (Mediatech Inc., Herdon, VA), incubating at 37°C in a 5% CO2 in 
air environment for five minutes.  Following incubation, cells were rinsed with 7 ml of 
αT3-1 media, with all cell suspensions collected.  A sample of cells (100 μl) was diluted 
in 900 μl of 1X PBS and 10 μl of this dilution loaded on a hemacytometer for cell counts. 
Approximately two million cells were plated onto 6-well cell culture dishes (Corning 
Inc.) in 2 ml of αT3-1 culture media. 
 
Day 2.  The plasmid used as a control for transfection efficiency was composed of 
the Rous Sarcoma Virus promoter fused to the cDNA encoding β-galactosidase (RSV- 
βgal, Stratagene, La Jolla, CA).  For each test vector, 291 μl of serum-free DMEM and 9 
μl of Fugene6 reagent (Roche Diagnostics Corp., Indianapolis, IN) were aliquoted into 
1.5-ml microcentrifuge tubes.  As each test vector was transfected in triplicate, sufficient 
quantities to result in 900 ng/well of test vector and 100 ng/well of RSV-βGal control 
vector were added to the microcentrifuge tube. The mixture was then incubated for a 
minimum of 15 minutes prior to adding 96 μl of the mixture (DMEM, Fugene6 and 
vectors) to each well. 
 
Day 3.  Transfected αT3-1 cells were harvested 20-24 hours after transfection. 
Media was aspirated from all wells, followed by two rinses with 1X PBS.  Lysis buffer 
(200 μl; Galacto-Light kit; Applied Biosystems, Bedford, MA) containing 1 M 
dithiothreitol (DTT) was added to each well and the plates were incubated, shaking at 
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4°C for 10 minutes.  Cell lysates and buffer were collected and centrifuged at 4°C for two 
minutes at 16,000 x g using a Spectrofuge 16M microcentrifuge (EandK Scientific, 
Campbell, CA).  Lysates (20 μl) were transferred to a white 96-well Microflux2 plate 
(Thermo Labsystems, Franklin, MA).  This was performed in duplicate for respective 
luciferase and β-galactosidase assays.  Plates were analyzed for luciferase and β- 
galactosidase activity using the Wallac Victor2 instrument (Perkin Elmer).  Transfections 
were performed a minimum of three times, using three different plasmid preparations. 
 
Protein Extraction 
Cytoplasmic and nuclear protein extracts were obtained from αT3-1 cells for their 
use  in electrophoretic mobility shift assays (EMSAs) using the NE-PER®  Nuclear and 
Cytoplasmic Extraction Reagents Kit (Pierce Biotechnology, Rockford, IL).  Four plates 
of αT3-1 cells at 70% confluency each were rinsed twice with 10 ml of 1X PBS before 
removing the cells via vigorous washing with buffer containing 10 mM Tris-Cl, 140 mM 
sodium chloride (NaCl), and 1 mM EDTA.  Cells were then removed from the wash 
buffer by centrifugation at 4°C for five minutes using a Beckman TJ-6 centrifuge at 500 x 
g (Beckman, Palo Alto, CA).  The resultant cell pellet was resuspended in CER I reagent 
through vortexing for 15 seconds and incubated on ice for 10 minutes.  Protease inhibitor 
cocktail (100X stock containing 104 mM AEBSF, 80 μM aprotinin, 2 mM leupeptin, 4 
mM bestatin, 150 μM pepstatin A and 140 μM E-64; Sigma Chemical Co.) and 
Phosphatase Inhibitor Cocktail Set  II (100X stock containing 200 mM imidazole, 100 
mM sodium fluoride, 115 mM sodium   molybdate,  100  mM  sodium  orthovanadate  
and  400  mM  sodium  tartrate dehydrate; CalBiochem, La Jolla, CA) were added 
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simultaneously with CER I reagent. CER II reagent was added to the cells, which were 
then vortexed and allowed to incubate on ice for one minute.  Following incubation, lysed 
cells were centrifuged at 4°C for five minutes  using  a  Spectrafuge  16M  
microcentrifuge  at  16,000  x  g  (EandK  Scientific, Campbell, CA), with resulting 
supernatant transferred to a clean 1.5-ml microcentrifuge tube and stored at -80°C.  The 
remaining pellet was resuspended in NER reagent with the addition of protease and 
phosphatase inhibitor cocktails and incubated on ice for 40 minutes with vortexing for 15 
seconds every 10 minutes.   Finally, lysed nuclei were centrifuged  at  4°C  for  10  
minutes  using  a  Spectrafuge  16M  microcentrifuge  (EandK Scientific) at 16,000 x g 
before being transferred to a clean 1.5-ml microcentrifuge tube.  Total protein 
concentration of nuclear extracts was quantitated using a BCA assay kit and the 
accompanying protocol (Pierce Biotechnology).   Nuclear extracts were stored at -80°C 
in 100 μl aliquots. 
 
Electrophoretic Mobility Shift Assays (EMSAs) 
 All  oligonucleotides  used  in  EMSAs  were  annealed  prior  to  use  by  adding 
complementary oligonucleotides (50 μM each) to 1X NET buffer (1 M NaCl, 10 mM 
EDTA, 100 mM Tris-Cl, pH 7.5) and Millipore water.  Oligonucleotides were first 
denatured by heating to 95°C for 10 minutes and then annealed by incubating at 37°C for 
30 minutes followed by a 30 minute incubation at 25°C. 
Oligonucleotides were end-labeled with [γ-32P]ATP using polynucleotide kinase 
(PNK; Fermentas Inc., Hanover, MD) and a forward reaction protocol.  Annealed 
oligonucleotide (1 μl) was incubated with 1 μl 10X PNK Buffer A, 4 μl water, 1 μl T4 
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PNK and 3 μl [γ-32P]ATP for 30 minutes at 37°C.  Following incubation, 35 μl of water 
was added to all reactions.  Reaction mixtures were then applied to equilibrated 
MicroSpin™ G-25 columns (Amersham Biosciences Corp., Piscataway, NJ) and 
centrifuged at 3,000 x g for two minutes using a Mikroliter microcentrifuge (Hettich AG, 
Bäch, Switzerland).  Following the addition of 10X NET buffer (5μl) to each reaction, 1 
μl from each reaction mixture was added to 4 ml of scintillation fluid and counted on a 
1900TR liquid scintillation counter (Packard Instrument Co., Meriden, CT). 
Electrophoretic mobility shift assays were performed by adding 2X Dignam D 
buffer (20 mM HEPES, 20% glycerol, 0.1 M potassium chloride, 0.2 mM EDTA, 0.5 
mM DTT), 20 mM DTT, and 2 μg poly(dI•dC) (Amersham Biosciences) to 5 μg of αT3-
1 nuclear extracts.  Probe labeled with [γ-32P]ATP (approximately 100,000 cpm) was 
added, and the reaction was incubated at room temperature for 20 minutes.  In those 
assays that included competitor oligonucleotides, the unlabeled, annealed competitor 
oligonucleotide was added just prior to the addition of radiolabeled probe.  For supershift 
assays, a rabbit polyclonal antibody directed against the p65 subunit of NF-κB 
(Calbiochem) or an equal amount of rabbit IgG (Santa Cruz Biotechnology, Santa Cruz,   
CA)   was   incubated   with   nuclear   extracts   and   binding   components   for 
approximately two hours at 4°C, prior to the addition of probe.  Polyacrylamide gels were 
subjected to electrophoresis in 1X TGE buffer (25 mM tris base, 190 mM glycine, 1 mM 
EDTA) for approximately one hour at 100V prior to the addition of binding reactions, 
with subsequent separation of bound from free probe by electrophoresis at 30 mA for 
approximately 1.5 hours.  Gels were then transferred to blotting paper (3 mm; Whatman, 
Maidstone,  England),  dried  and  exposed  to  Biomax  MS  film  (Eastman  Kodak  Co., 
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Rochester, NY) for 20-24 hours at -80°C before being developed using an SRX-101A 
medical film developer (Konica Corp., Wayne, NJ). 
 
Western Blot 
 Nuclear proteins from αT3-1 cells were extracted using the NE-PER®  Nuclear and 
Cytoplasmic Extraction Reagent Kit per manufacturer’s instructions (Pierce 
Biotechnology, Rockford, IL), quantitated with a BCA Protein Assay (Pierce) and stored 
at -80 C.  Protein samples (40 μg) were boiled for 5 min in a 2X reducing loading buffer 
(130 mM Tris pH 6.8, 4% SDS, 0.02% Orange G, 20% glycerol, 100 mM DTT), cooled 
to room temperature and loaded onto an SDS polyacrylamide gel (PAGE) with a 5% 
stacking and 10% resolving gel.  Gels were run at 40 mA for approximately 90 min and 
electrophoresed proteins were transferred to polyvinylidene difluoride (PVDF, 
Immobilon –FL, Millipore, Billerica, MA) membrane with a semi-dry electroblotter 
(Panther, Owl Separation Systems, Portsmouth, NH).  Briefly, PVDF membrane was pre-
wetted in 100% methanol and soaked with the gel in transfer buffer (25 mM Tris pH 8.3, 
192 mM glycine, 0.1% SDS, 20% methanol) for 15 min.  The proteins were transferred at 
200 mA for 1 h.  Membranes were blocked with StartingBlock™ (TBS) Buffer (Pierce) 
for 30 min at room temperature with agitation.  Incubation of primary antibody directed 
against the GR (Santa Cruz Biotechnology) was performed in StartingBlock™ (TBS) 
Buffer (Pierce) supplemented with 0.05% Tween-20.  Antibody was used at 1:1000 
dilutions.  Blots were incubated with primary antibody overnight at 4 C with gentle 
shaking.  After incubation the blots were washed four times with TBS-T (20 mM Tris pH 
7.6, 137 mM sodium chloride, 0.1% Tween-20).  Each wash was performed for 5 min 
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with gentle agitation.  The secondary antibody, Alexa Fluor 680 goat anti-rabbit IgG 
(A21076, Invitrogen, Carlsbad, CA) was diluted 1:8000 in StartingBlock™ (TBS) Buffer 
(Pierce) supplemented with 0.01% SDS and 0.05% Tween-20.  The incubation was 
performed at room temperature for 1 h with gentle shaking.  Blots were washed four 
times in TBS-T for 5 min with gentle agitation.  After a final rinse with TBS, blots were 
scanned on the 700 channel of the Odyssey Infrared Imaging System (LI-COR, Lincoln, 
NE) following manufacturer’s instructions. 
 
Biotinylated DNA and Protein Pull-down Assay 
We performed pull down assay according to a procedure described by Deng et al. 
(2003) with minor modifications (Figure 3.1).  In brief, 5 ug of 5’-biotinylated DNA 
promoter probe containing GRE was mixed with 500 ug of nuclear extract from αT3-1 
cells treated with vehicle or 100 nM dexamethasone and 100 ul of 4 % streptavidin-
agarose beads in Pierce Biotinylated Protein Interaction Pull-Down Kit (product no. 
2115, Thermo Fisher Scientific Inc., Rockford, IL).  The final volume was adjusted to 
500 ul with nuclear extract buffer from the pull-down kit.   The mixture was incubated at 
room temperature for 1 h with gentle shaking and centrifuged at 5000 × g in a 
microcentrifuge for 30 sec.  The supernatant was removed and the pellet was washed four 
times with 1 ml of iced PBS.  The pulled down mixture, then, was resuspended in 50 ul 
of Laemmli sample buffer (Bio-Rad) and boiled for 5 min.  25 ul of the samples was 
placed in a 4-20 % gradient polyacrylamine minigel to perform SDS-PAGE. 
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Figure 3.1.  Diagram of biotinylated DNA/protein pull-down assay, SDS-PAGE, and 
Mass Spectrometry. In order to identify which protein binds to the 290/270 bp region 
during the dex treatment, I utilized a DNA pull-down assay to isolate the oligonucleotide-
protein complex, and then separated proteins comprising the complex using SDS-PAGE.  
In the gel, protein band was captured between 95kDa and 130kDa in both treatments.  
Spots of interest were then excised from the SDS-PAGE gel and sent to the Nebraska 
Center for Mass Spectrometry for protein identification. Mass spectrometry results from 
both vehicle and 100 nM dexamethasone treated cells revealed Poly (ADP ribose) 
polymerase-1 protein. 
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Mass Spectrometry 
Spots of interest were excised from the SDS-PAGE gel (Figure 3.1) and sent to 
the Nebraska Center for Mass Spectrometry (Lincoln, NE) for protein identification using 
tandem mass spectrometry (MS/MS) with a Waters Q-TOF Ultima mass spectrometer 
(Micromass/Waters, Milford, MA; Figure 3.1).  Briefly, excised bands were digested 
using the method of Shevchenko et al. (1997) in which samples were washed with 
100 mM ammonium bicarbonate, reduced with 10 mM DTT, alkylated with 55 mM 
iodoacetamide, washed twice with 100 mM ammonium biocarbonate, digest in situ with 
10 ng μl−1 trypsin, and extracted with two 60 μl aliquots of 1:1 acetonitrile:water (v/v) 
containing 1% formic acid.  The resulting peptides were separated on a C18 reversed 
phase column (75 μm × 15 cm; LC-Pacings, Dionex, Sunnyvale, CA), and eluted using a 
water + 0.1% formic acid (A)/95% acetonitrile:5% water + 0.1% formic acid (B) gradient 
with a 270 nl/min flow rate.  The MS/MS data were processed to produce peak lists for 
database searching.  Sequences were further searched against Matrix Science Database 
20060908 (www.matrixscience.com) for peptide mass fingerprints of mouse (52735 
sequences in the database) with the significance threshold set at P < 0.05.  Molecular 
weight search scoring (MOWSE) used an algorithm described in Pappin et al. (1993) to 
determine the “rank” of the peptide compared to all matches in the database. MOWSE 
was also used in conjunction with the percent coverage and individual ion scores (not 
shown) for each amino acid in the peptide to verify homology or the identity of the 
protein. 
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Bioinformatics and Statistical Analysis 
 Analyses of sequence for transcription factor binding sites were performed with 
the Patch Public 1.0 program (Biobase, Wolfenbüttel, Germany).  Data were analyzed 
using the general linear models (GLM) procedure of the Statistical Analysis System 
software (version 8.2, SAS Institute Inc, Cary, NC).  Means for luciferase activity of test 
vectors were compared with control values using Dunnett’s t-test, whereas means for 
luciferase activity among test vectors were compared using Tukey’s Studentized Range 
test.  Transfections were performed in triplicate with at least three replicates containing 
different plasmid preparations. 
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CHAPTER IV 
 
Role of Poly [ADP-ribose] Polymerase-1 (PARP-1) as a Transcription Factor in 
Glucocorticoid Regulation of the Porcine GnRH Receptor (GnRHR) Gene. 
 
ABSTRACT 
The binding of GnRH to its receptor results in the synthesis and secretion of the 
gonadotropins, as well as stimulation of the gene encoding its own receptor. Thus, the 
interaction between GnRH and GnRHR represents a central point for regulation of 
reproductive function. Glucocorticoids can alter reproduction by reducing GnRH 
responsiveness of gonadotropes within the anterior pituitary gland, potentially via 
transcriptional regulation of the GnRHR gene. Investigation of this possible mechanism, 
however, revealed that transcription of the murine GnRHR gene is stimulated by 
glucocorticoids. To determine the effect of glucocorticoids on porcine GnRHR gene 
expression, gonadotrope-derived αT3-1 cells were transiently transfected with a vector 
containing 5118 bp of 5’ flanking sequence for the porcine GnRHR gene fused to 
luciferase for 12 h and treated with increasing concentrations of the glucocorticoid 
agonist, dexamethasone (0, 1, 10, 100 and 1,000 nM) for an additional 12 h prior to 
harvest. Maximal induction of luciferase activity was detected at 100 nM of 
dexamethasone (2-fold over vehicle; P < 0.05), and this response was blocked by the 
glucocorticoid antagonist, mifepristone (100 pM). Deletion from 274 to 323 bp upstream 
of the translational start site eliminated glucocorticoid responsiveness, suggesting the 
presence of a GRE(s) within this region. Electrophoretic mobility shift assays (EMSA) 
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using a 32P-labeled oligonucleotide spanning -290/-270 bp of proximal promoter 
revealed increased binding of nuclear extracts from αT3-1 cells treated with 100 nM 
dexamethasone compared to vehicle. Sequence analysis of this region indicated putative 
binding sites for PR, ER, GR, COUP-TF and GATA, as well as RXR α, β, and γ. 
However, competitive oligonucleotides for each of these transcription factors, including 
GR, were unable to compete for binding to the radiolabeled -290/-270 bp probe in 
EMSAs. Mass spectrometry analysis of isolated proteins from a pull-down using a 
biotinylated oligonucleotide (-290/-270 bp) identified PARP-1 as the key binding partner.  
To confirm the mass spectrometry result, we performed EMSAs with antibodies specific 
for either GR or PARP-1. Both the GR and PARP-1 antibodies generated a supershift of 
the specific binding complex. Interestingly, addition of the PARP-1 and GR antibodies 
together abolished the supershift. Since the competitive oligonucleotide for GR was 
unable to abrogate the DNA/protein complex, whereas inclusion of antibodies confirmed 
that GR was a member of the specific binding complex, this suggests that GR must 
recruit PARP-1 in order to bind the GRE. Inhibition of p38 and ERK1/2 mitogen-
activated protein kinase (MAPK) pathways significantly decreased dexamethasone-
induced promoter activity (P < 0.05), indicating the involvement of these signaling 
pathways in glucocorticoid stimulation of the promoter. Thus, our working model for 
glucocorticoid responsiveness of the porcine GnRHR gene suggests that, upon binding to 
its receptor, glucocorticoid triggers phosophorylation of GR by p38 and ERK1/2 MAPK 
pathways, resulting in the recruitment of PARP-1 by phosphorylated, ligand-bound GR to 
a GRE located within -290/-270 bp of the porcine GnRHR promoter. 
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Introduction 
The decapeptide gonadotropin-releasing hormone (GnRH) is a key factor that 
mediates the function of the hypothalamic-pituitary-gonadal axis in mammals.  Generated 
by hypothalamic neurons, GnRH is released in an intermittent manner, traveling to 
gonadotropes in the anterior pituitary gland via the hypothalamo-hypophyseal portal 
system (Fink, 1988).  Gonadotropin-releasing hormone binds to high-affinity receptors on 
gonadotrope cells resulting in the biosynthesis and secretion of both follicle stimulating 
hormone (FSH) and luteinizing hormone (LH), which stimulate steroid synthesis and 
gametogenesis in the gonads (Clayton and Catt, 1981; Clarke et al., 1983; Mason et al., 
1986).  Upon binding to its receptor, GnRH regulates expression of at least 4 
gonadotropic genes including those encoding: the common α-glycoprotein subunit, the 
specific LHβ- and FSHβ-subunits that combine to produce LH or FSH (Hamernik and 
Nett, 1988; Gharib et al., 1990), and the GnRH receptor (GnRHR) itself (Sealfon and 
Millar, 1995).  Transcriptional regulation of GnRHR is mediated by GnRH via protein 
kinase A (PKA) and C (PKC) activation of multiple mitogen-activated protein kinase 
(MAPK) pathways including extracellular signal-regulated kinase (ERK), c-Jun N-
terminal kinase (JNK), p38 MAPK, and ERK5, also known as big MAPK1 (BMK1; 
Sundaresan et al., 1996; Roberson et al., 1999; Noar et al., 2000; Liu et al., 2003; Bonfil 
et al., 2004). Thus, the interaction between GnRH and its receptor represents a central 
point for regulation of reproductive function in mammals. 
Many studies have examined responsiveness of the GnRHR gene to hormones 
including GnRH (White et al., 1999; Norwitz et al., 1999; Ellsworth et al., 2001; Liu et 
al., 2003), estradiol-17β (Gregg et al., 1990; Laws et al., 1990; Wu et al., 1994; Duval et 
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al., 2000), progesterone (Laws et al., 1990; Cheng et al., 2001), testosterone (Kaiser et al., 
1993; Curtin et al., 2001; Zapatero-Caballero et al., 2003) activin (Fernandez-Vazquez et 
al., 1996; Pernasetti et al., 2001; Norwitz et al., 2002), and inhibin (Braden et al., 1990; 
Gregg et al., 1991; Wu et al., 1994). Several reports indicated that GnRH regulates 
GnRHR numbers and mRNA levels in the pituitary gland from the rat (Pieper et al., 1982; 
Clayton et al., 1982; Kaiser et al., 1993; Bauer-Dantoin et al., 1995), sheep (Turzillo et al., 
1994), and cow (Vizcarra et al., 1997). In contrast, others reported no change in amounts 
of GnRHR mRNA after GnRH treatment in the gonadotrope-derived αT3-1 cell line 
(Tsutsumi et al., 1993, 1995; Alarid and Mellon, 1995). Besides regulation of the level of 
GnRHR mRNA, GnRH can both up- and down-regulate receptor numbers in the pituitary 
(McArdle et al., 1987; Uemura et al., 1992; Bauer-Dantoin et al., 1993; Conn et al., 1995). 
Norwitz et al. (1999) determined two elements involved in GnRH responsiveness, 
sequence underlying responsiveness to GnRH-1 and 2 (SURG-1 and SURG-2, 
respectively) and Kam et al. (2005) reported that nuclear factor Y (NF-Y) and octamer 
transcription factor-1 (Oct-1) bind to the SURG-1 element to increase basal and GnRH-
stimulated expression of the mouse GnRHR gene.  White et al. (1999) isolated an 
activation protein-1 (AP-1) element within SURG-2 that conferred GnRH responsiveness 
of the GnRHR promoter. Moreover, these investigators identified that GnRH regulation 
of the GnRHR gene was mediated via activation of an AP-1 element by PKC (White et 
al., 1999) and the JNK pathway (Ellsworth et al., 2003).  In addition, the GnRHR 
activating sequence (GRAS), important to basal promoter activity, also mediated activin 
responsiveness in the mouse GnRHR gene (Duval et al., 1999).  The binding of Smad3 
and 4 proteins to GRAS (Duval et al., 2000) and AP-1 complexes to an overlapping AP-1 
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element regulated activin responsiveness (Ellsworth et al., 2003).  Further studies 
demonstrated that binding of the LIM homeodomain proteins, LHX2 and 3, to a 
downstream activin regulatory element (DARE) is also necessary for activin 
responsiveness (Cherrington et al., 2005; Cherrington et al., 2006).  
Glucocorticoids can act at both the hypothalamus and anterior pituitary gland to 
regulate gonadotropin secretion (Brann and Mahesh, 1991; Tilbrook et al., 2000).  Recent 
investigations into stress-related influences on reproductive function implicated 
glucocorticoids in the physiological regulation of GnRH and its receptors.  For example, 
glucocorticoids acted directly at the hypothalamus to suppress GnRH synthesis 
(Chandran et al., 1994) and reduced the activity of the GnRH pulse-generating center 
(Dubey and Plant, 1985).  Similarly, in the anterior pituitary gland, glucocorticoids 
decreased GnRH responsiveness of gonadotrope cells (Kamel and Kubajak, 1987; 
Baldwin et al., 1991).  In contrast to inhibition of GnRH secretion from the hypothalamus 
and reduced responsiveness of gonadotropes to GnRH, glucocorticoids also increased 
GnRHR mRNA and protein levels.  In male rats, the glucocorticoid agonist, 
dexamethasone, acted directly on gonadotrope cells to modulate a GnRH-induced 
increase in GnRHR numbers, as well as gonadotropin gene expression and secretion 
(Rosen et al, 1991).  In addition, dexamethasone treatment increased endogenous GnRHR 
mRNA levels in the gonadotrope-derived LβT2 cell line (Turgeon et al., 1996) and 
activity of the murine GnRHR promoter in pituitary adenoma-derived GGH3 (Maya-
Núñez and Conn, 2003) and LβT2 (McGillivray et al., 2007) cells.  Maya-Núñez and 
Conn (2003) identified the glucocorticoid response element (GRE) as an AP-1 binding 
site located between 255 and 331 bp upstream of the transcriptional start site that bound 
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the transcription factor, c-Jun, suggesting that ligand-bound glucocorticoid receptors 
interact directly or indirectly with c-Jun to regulate GnRHR transcription.  Our laboratory 
has isolated the porcine GnRHR gene promoter and identified elements conferring basal 
activity in αT3-1 cells.  The objectives of this study are to determine glucocorticoid 
responsiveness of the porcine GnRHR gene, to isolate the  glucocorticoid response 
element(s) located within the porcine GnRHR promoter and to examine the molecular 
mechanisms underlying glucocorticoid stimulation of GnRHR gene expression in αT3-1 
cells. 
 
Materials and Methods 
 
Materials.  Dexamethasone and mifepristone (RU486) were from Sigma 
Chemical Co. (St. Louis, MO) and Org 31710 was a generous gift from N.V. Organon 
(Oss, Netherlands).  The antibody specific for the PARP-1 (catalog no. 614301) was 
purchased from BioLegend (San Diego, CA); and the specific antibody for the GR 
(catalog no. sc-1004X) and normal rabbit IgG (catalog no. sc-2027) were obtained from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  For experiments using EMSA, DNA 
probe (-290/-270; sense sequence 5’-TTGTGAAAACCAGGCCATCTG-3’ and antisense 
sequence 5’-CAGATGGCCTGGTTTTCACAA-3’) and competitive oligonucleotides 
containing consensus binding sites for transcription factor were synthesized by Integrated 
DNA Technologies (IDT, Coralville, IA).  Biotinylated DNA probe 
(5’biotin/TTGTGAAAACCAGGCCATCTG-3’) was also synthesized by IDT for 
biotinylated DNA-pull down assays. 
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Plasmids.  A reporter vector containing 5118 bp of porcine GnRHR promoter (-
5118pGL3) was constructed by PCR amplification of the 5’ flanking region of the GnRH 
receptor gene from genomic DNA preparations of pigs representing a white crossbred 
line.  The PCR product was subsequently subcloned into pBluescript SK- (Stratagene, La 
Jolla, CA).  Promoter inserts were ligated into a reporter vector containing the cDNA 
encoding luciferase (pGL3; Promega Corp., Madison, WI) at the SacI/EcoRV location of 
the multiple cloning site.  Deletion constructs were made by progressively removing 5’ 
flanking sequence (approximately 500 bp) via restriction enzyme digests and subsequent 
intramolecular ligation of the remaining vector backbone.  Construction of the 100-bp 
deletion reporter vectors was achieved by amplifying the specified region of the promoter 
by PCR with a Taq DNA polymerase containing 3’ to 5’ exonuclease activity (Bioline, 
Springfield, NJ).  Next, the fragments were subcloned into pBluescript SK- or pCR-Blunt 
II (Invitrogen, Carlsbad, CA), and then finally into pGL3. 
 
Cell Culture and Transfections.  αT3-1 (Dr. Pam Mellon, Salk Institute, La 
Jolla, CA) cells were maintained at 37 C in a humidified 5% CO2 in air atmosphere.  The 
αT3-1 cells were cultured in high-glucose DMEM (Mediatech, Herndon, VA) 
supplemented with 5% fetal bovine serum (FBS), 5% horse serum, 2 mM glutamine, 100 
U/ml penicillin, and 100 µg/ml streptomycin sulfate (Gibco, Grand Island, NY). 
Transient transfections were performed using a liposome-mediated protocol (Fugene6; 
Roche Diagnostics Corp., Indianapolis, IN) following manufacturer’s instructions.  The 
day prior transfection, cells were plated in 6-well tissue culture plates at the appropriate 
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density (between 2 x 10
5
 and 2 x 10
6
 cells) to result in 40% confluency on the day of 
transfection.  Cells were transfected with a 3:1 Fugene6 to DNA ratio.  A total of 1 µg of 
DNA, 0.9 µg of luciferase test vector and 0.1 µg of pSV-β-gal were used per well.  
Luciferase (Promega Corp.) and β-gal assays (Applied Biosystems, Bedford, MA) were 
performed following manufacturer’s instructions.  After 12 h transfection, cells were 
treated with dexamethasone or progesterone. If mentioned, antagonists were added into 
cells 15 min prior to agonist treatment.  At 24 h post transfection, cells were washed 
twice with ice-cold PBS and harvested with 200 µl of lysis buffer [100 mM potassium 
phosphate (pH 7.8), 0.2% Triton X-100 and 1 mM dithiothreitol (DTT)].  Lysates were 
cleared by centrifugation at 16,000 x g for 2 min at 4 C and 20 µl of lysate was used to 
perform each of the assays.  Luciferase and β-gal values for each sample were determined 
using a Wallac VICTOR
2
 micro plate reader (PerkinElmer Life Sciences, Boston, MA).  
To normalize for transfection efficiency, luciferase activity was divided by β-gal values. 
 
Electrophoretic Mobility Shift Assays.  Nuclear protein extracts were prepared 
from αT3-1 cells utilizing the NE-PER®  Nuclear and Cytoplasmic Extraction Reagent Kit 
according to manufacturer’s instructions (Pierce Biotechnology, Rockford, IL).  
Approximately 2.8 x 10
8
 αT3-1 cells were harvested with TNE buffer [10 mM Tris (pH 
8), 140 mM NaCl, 1 mM EDTA], and the extracts were treated with protease (catalog no. 
P8340; Sigma Chemical Co.) and phosphatase (catalog no. 524625; Calbiochem, La 
Jolla, CA) inhibitor cocktails to prevent enzymatic degradation of proteins.  The amount 
of protein present in the extracts was determined using a bicinchoninic acid (BCA) assay 
(Pierce Biotechnology).  Oligonucleotide probes were end-labeled with [γ-32P]ATP using 
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T4 polynucleotide kinase (MBI Fermentas Inc., Hanover, MD) and purified using 
sephadex G-25 spin columns (Amersham Biosciences Corp., Piscataway, NJ).  Nuclear 
extracts (5 μg) were incubated with 4 μl of Dignam D buffer (20 mM HEPES, 20% 
glycerol, 0.1 M potassium chloride, 0.2 mM EDTA, 0.5 mM DTT), 1 mM DTT, 2 μg 
poly(dI•dC) (Amersham Biosciences Corp.) and, where indicated, rabbit antiserum 
directed against GR (catalog no. sc-1004X; Santa Cruz Biotechnology) or an equal 
amount of rabbit IgG (catalog no. sc-2027; Santa Cruz Biotechnology) at 25 C for 30 
min.  Following incubation, radiolabeled probe (100,000 cpm) was added and, where 
indicated, 50-fold molar excess of either homologous or heterologous unlabeled 
competitor.  Reactions were incubated for an additional 20 min at 25 C before free probe 
was separated from bound probe by electrophoresis for 1.5 h at 30 mA in 5 % 
polyacrylamide gels that were prerun for 1 h at 100 V in 1 X TGE [25 mM Tris (pH 8.3), 
190 mM glycine and 1 mM EDTA].  Gels were transferred to blotting paper, dried, and 
exposed to Biomax MS film (Eastman Kodak Co., Rochester, NY) for 20-24 h at -80 C 
before being developed.   
 
Western Blot.  Nuclear proteins from αT3-1 cells were extracted using the NE-
PER
®
 Nuclear and Cytoplasmic Extraction Reagent Kit per manufacturer’s instructions 
(Pierce Biotechnology), quantitated with a BCA Protein Assay (Pierce Biotechnology) 
and stored at -80 C.  Protein samples (40 μg) were boiled for 5 min in a 2X reducing 
loading buffer (130 mM Tris pH 6.8, 4% SDS, 0.02% Orange G, 20% glycerol, 100 mM 
DTT), cooled to room temperature and loaded onto an SDS polyacrylamide gel (PAGE) 
with a 5% stacking and 10% resolving gel.  Gels were run at 40 mA for approximately 90 
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min and electrophoresed proteins were transferred to polyvinylidene difluoride (PVDF; 
Immobilon –FL; Millipore, Billerica, MA) membrane with a semi-dry electroblotter 
(Panther; Owl Separation Systems, Portsmouth, NH).  Briefly, PVDF membrane was pre-
wetted in 100% methanol and soaked with the gel in transfer buffer (25 mM Tris pH 8.3, 
192 mM glycine, 0.1% SDS, 20% methanol) for 15 min.  The proteins were transferred at 
200 mA for 1 h.  Membranes were blocked with StartingBlock™ (TBS) Buffer (Pierce 
Biotechnology) for 30 min at room temperature with agitation.  Incubation of primary 
antibody directed against the GR (Santa Cruz Biotechnology) was performed in 
StartingBlock™ (TBS) Buffer (Pierce Biotechnology) supplemented with 0.05% Tween-
20.  Antibody was used at 1:1000 dilutions.  Blots were incubated with primary antibody 
overnight at 4 C with gentle shaking.  After incubation the blots were washed four times 
with TBS-T (20 mM Tris pH 7.6, 137 mM sodium chloride, 0.1% Tween-20).  Each 
wash was performed for 5 min with gentle agitation.  The secondary antibody, Alexa 
Fluor 680 goat anti-rabbit IgG (catalog no. A21076, Invitrogen) was diluted 1:8000 in 
StartingBlock™ (TBS) Buffer (Pierce Biotechnology) supplemented with 0.01% SDS 
and 0.05% Tween-20.  The incubation was performed at room temperature for 1 h with 
gentle shaking.  Blots were washed four times in TBS-T for 5 min with gentle agitation.  
After a final rinse with TBS, blots were scanned on the 700 channel of the Odyssey 
Infrared Imaging System (LI-COR, Lincoln, NE) following manufacturer’s instructions. 
 
Biotinylated DNA and Protein Pull-down Assay.  We performed pull down 
assays according to a procedure described by Deng et al. (2003) with minor 
modifications.  In brief, 5 ug of 5’-biotinylated DNA promoter probe containing GRE 
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was mixed with 500 ug of nuclear extract from αT3-1 cells treated with vehicle or 100 
nM dexamethasone and 100 ul of 4 % streptavidin-agarose beads in Pierce Biotinylated 
Protein Interaction Pull-Down Kit (product no. 2115; Pierce Biotechnology).  The final 
volume was adjusted to 500 ul with nuclear extract buffer from the pull-down kit.   The 
mixture was incubated at room temperature for 1 h with gentle shaking and centrifuged at 
5000 × g in a microcentrifuge for 30 sec.  The supernatant was removed and the pellet 
was washed four times with 1 ml of iced PBS.  The pulled down mixture, then, was 
resuspended in 50 ul of Laemmli sample buffer (Bio-Rad) and boiled for 5 min.  25 ul of 
the samples was placed in a 4-20 % gradient polyacrylamine minigel to perform SDS-
PAGE.    
 
Mass Spectrometry.  Spots of interest were excised from the SDS-PAGE gel and 
sent to the UNL Center for Mass Spectrometry (Lincoln, NE) for protein identification 
using tandem mass spectrometry (MS/MS) with a Waters Q-TOF Ultima mass 
spectrometer (Micromass/Waters, Milford, MA).  Briefly, excised bands were digested 
using the method of Shevchenko et al. (1997) in which samples were washed with 
100 mM ammonium bicarbonate, reduced with 10 mM DTT, alkylated with 55 mM 
iodoacetamide, washed twice with 100 mM ammonium biocarbonate, digest in situ with 
10 ng μl−1 trypsin, and extracted with two 60 μl aliquots of 1:1 acetonitrile:water (v/v) 
containing 1% formic acid.  The resulting peptides were separated on a C18 reversed 
phase column (75 μm × 15 cm; LC-Pacings, Dionex, Sunnyvale, CA), and eluted using a 
water + 0.1% formic acid (A)/95% acetonitrile:5% water + 0.1% formic acid (B) gradient 
with a 270 nl/min flow rate.  The MS/MS data were processed to produce peak lists for 
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database searching.  Sequences were further searched against Matrix Science Database 
20060908 (www.matrixscience.com) for peptide mass fingerprints of mouse (52735 
sequences in the database) with the significance threshold set at P < 0.05.  Molecular 
weight search scoring (MOWSE) used an algorithm described by Pappin et al. (1993) to 
determine the “rank” of the peptide compared to all matches in the database. MOWSE 
was also used in conjunction with the percent coverage and individual ion scores (not 
shown) for each amino acid in the peptide to verify homology or the identity of the 
protein. 
 
Bioinformatics and Statistical Analysis.  Analyses of sequence for transcription 
factor binding sites were performed with the Patch Public 1.0 program (Biobase, 
Wolfenbüttel, Germany).  Data were analyzed using the general linear models (GLM) 
procedure of the Statistical Analysis System software (version 8.2, SAS Institute Inc, 
Cary, NC).  Means for luciferase activity of test vectors were compared with control 
values using Dunnett’s t-test, whereas means for luciferase activity among test vectors 
were compared using Tukey’s Studentized Range test.  Transfections were performed in 
triplicate with at least three replicates containing different plasmid preparations. 
 
Results 
Activity of the porcine GnRHR promoter is regulated by dexamethasone in 
dose-dependent manner.  To investigate glucocorticoid responsiveness of the porcine 
GnRHR gene, we performed transient transfections in αT3-1 cells with luciferase reporter 
plasmids containing the full-length porcine GnRHR  promoter (-5118pGL3) followed by 
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treatment with increasing concentrations of the glucocorticoid agonist, dexamethasone, or 
100 nM dexamethasone in combination with increasing amounts of glucocorticoid 
antagonist, mifepristone (RU 486; Figure 4.1).  Treatment with increasing amounts of 
dexamethasone resulted in a dose-dependent increase in promoter activity (P < 0.05) and 
optimal promoter activity occurred after treatment with 100 nM of dexamethasone (2-
fold).  To confirm specificity of this response, we treated cells with 100 nM 
dexamethasone and increasing amounts of RU 486 (Figure 4.1).  Dexamethasone-induced 
promoter activity was reduced to basal levels following treatment with 100 pM RU 486, 
suggesting that GR or PR may mediate glucocorticoid responsiveness of the porcine 
GnRHR gene (Figure 4.1).  Although 10 pM is within the range of GR-specific inhibition 
for RU 486, this inhibitor can also interact with PR a dfferent binding affinities. 
 
Dexamethasone responsiveness of the porcine GnRHR gene is mediated by 
GR and GR translocation to nucleus.  To investigate whether dexamethasone 
responsiveness of the porcine GnRHR gene was mediated by GR or PR, we transiently 
transfected αT3-1 cells with luciferase reporter plasmids containing the full-length 
porcine GnRHR gene promoter (-5118pGL3) and treated with increasing concentrations 
of dexamethasone or 100 nM dexamethasone in combination with increasing amounts of 
the progesterone antagonist, Organon 31710 (Org31710; Figure 4.2).  It has been 
reported that Org31710 has a similar relative binding affinity for cytoplasmic PR as RU 
486, but a much lower binding affinity (over 30-fold) for GR than RU 486 (Kloosterboer 
et al., 1994).  Similar to results shown in Figure 4.1, dexamethasone-induced luciferase 
activity of the GnRHR gene increased in a dose-dependent manner.  However, increasing   
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Figure 4.1.  Luciferase activity of αT3-1 cells transiently transfected with porcine 
GnRHR promoter constructs following treatment with increasing concentrations of the 
glucocorticoid agonist, dexamethasone, or 100 nM dexamethasone in combination with 
increasing amounts of the glucocorticoid antagonist, RU486. αT3-1 cells were transfected 
with luciferase reporter (LUC) vectors containing the full length porcine GnRHR 
promoter. After 12 h, cells were treated with 0.001, 0.01, 0.1, and 1 uM dexamethasone 
or combinations of 0.1 uM dexamethasone and 0.0001, 0.001, 0.01, 0.1, or 1 nM RU486. 
RU486 was added to cells 15 min prior to dexamethasone treatment. Cells were co-
transfected with RSV-β-gal and, after 24 h of transfection, cells were harvested and 
cellular lysates were assayed for LUC and β-gal activity.  To control for transfection 
efficiency, LUC activity was divided by β-gal values and results are expressed as fold 
expression over pGL3.  Optimal promoter activity occurred after treatment with 0.1 uM 
dexamethasone and activity was reduced to basal levels by 0.1 nM RU486.  
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Figure 4.2.  Luciferase activity of αT3-1 cells transiently transfected with porcine 
GnRHR promoter constructs following treatment with increasing concentrations of the 
glucocorticoid agonist, dexamethasone, or 100 nM dexamethasone in combination with 
increasing amounts of the progesterone antagonist, Org31710.  αT3-1 cells were 
transfected with the full length porcine GnRHR promoter. After 12 h, cells were treated 
with 0.001, 0.01, 0.1, or 1 uM dexamethasone or combinations of 0.1 uM dexamethasone 
and 0.0001, 0.001, 0.01, 0.1, or 1 nM Org31710. Org31710 was added to cells 15 min 
prior to dexamethasone treatment. Optimal promoter activity occurred after treatment 
with 0.1 uM dexamethasone and activity was reduced to basal levels by 1 nM RU486. 
Bars with asterisks are different from controls (P < 0.05). 
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amounts of Org31710, at concentrations similar to RU 486, were unable to reduce 
dexamethasone-stimulated luciferase activity (Figure 4.2).  Therefore, this result indicates 
that dexamethasone regulates the porcine GnRHR gene through binding to GR.  
Interestingly, 1 nM Org31710 treatment eliminated dexamethasone-induced promoter 
activity.  However, this is due to the fact that Org 31710 has an affinity for both GR and 
PR (Kloosterboer et al., 1994).  
 Typically, GRs are located within the cytoplasm of the cell in unstimulated 
conditions (Dittmar et al., 1997; Hawle et al., 2006).  In the presence of ligands, however, 
GRs are dimerized and translocated to the nucleus (Croxtall et al., 2000; Ford et al., 1997 
Glass and Rosenfeld, 2000).  To examine the translocation of GR in αT3-1 cells, we 
treated αT3-1 cells with vehicle and 100 nM dexamethasone and analyzed proteins from 
these cells using Western blot analysis (Figure 4.3).  Nuclear extracts from αT3-1 cells 
treated with 100 nM dexamethasone expressed more GR protein in the nucleus compared 
to those treated with vehicle.  This indicates GR translocation during dexamethasone 
exposure.  
 
Sequential 5’ deletions of the full-length porcine reporter construct 
demonstrates that the 290/270 bp region of porcine GnRHR promoter is critical for 
dexamethasone responsiveness.  To determine the location of the glucocorticoid 
response element (GRE), we investigated dexamethasone responsiveness of αT3-1 cells 
transiently transfected with reporter vectors containing sequential deletion of 5’ flanking 
sequences for the porcine GnRHR gene (Figure 4.4).  Reduction of proximal promoter 
from 5000 to 320 bp had no effect on dexamethasone-stimulated luciferase activity (P > 
80 
 
   
 
Figure 4.3.  Determination of the translocation of GR following treatment with vehicle or 
100 nM dexamethasone using western blot analysis.  Detailed protocols are described in 
Materials and Methods. Briefly, nuclear extracts (40 μg) were boiled for 5 min in a 2X 
reducing loading buffer, cooled to room temperature and loaded onto an SDS 
polyacrylamide gel (PAGE) with a 5% stacking and 10% resolving gel.  Gels were run at 
40 mA for approximately 90 min and electrophoresed proteins were transferred to 
polyvinylidene difluoride (PVDF, Immobilon –FL, Millipore, Billerica, MA) membrane 
with a semi-dry electroblotter (Panther, Owl Separation Systems, Portsmouth, NH).  
Incubation of primary antibody directed against the GR (Santa Cruz Biotechnology) was 
performed in StartingBlock™ (TBS) Buffer (Pierce) with 0.05% Tween-20 at 1:1000 
dilutions.  The secondary antibody, Alexa Fluor 680 goat anti-rabbit IgG (A21076, 
Invitrogen, Carlsbad, CA) was diluted 1:8000 in StartingBlock™ (TBS) Buffer (Pierce) 
supplemented with 0.01% SDS and 0.05% Tween-20.  GR concentration was increased 
in nucleus while decreased in cytoplasm when αT3-1 cells were treated with 100nM 
dexamethasone. This indicates nuclear translocation of the GR in αT3-1 cells during 
dexsamethasone stimulation. 
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0.05).  However, reduction of the promoter from 320 to 270 bp reduced luciferase 
activity to basal levels (P < 0.05).  Additional deletion vectors within 320 and 270 bp 
region were constructed to more precisely locate the GRE (Figure 4.5).   The vector 
containing the 320 to 290 bp region of the porcine promoter maintained dexamethasone-
induced luciferase activity, whereas a complete loss in dexamethasone-induced luciferase 
activity was observed when the promoter was reduced to 270 bp (P < 0.05).  Therefore, 
this result suggests that a glucocorticoid response element(s) is located within the -290/-
270 bp region upstream of the translational start site for the porcine GnRHR promoter. 
 
EMSAs revealed that increased protein binding to the -290/-270 bp promoter 
region is responsible for dexamethasone-induced activity of the porcine GnRHR 
gene.  EMSAs were performed with αT3-1 nuclear extracts and radiolabeled probe 
spanning -290/-270 bp region generated from the porcine GnRHR promoter to identify 
binding factor(s) within the -290/-270 region.  Results indicated increased specific 
binding complexes to the nuclear extracts from αT3-1 cells treated with 100 nM 
dexamethasone compared to vehicle (Figure 4.6).  Sequence analysis of this region has 
revealed several putative transcription factor binding sites including estrogen receptor 
(ER), progesterone receptor (PR), glucocorticoid receptor (GR), signal transducer and 
activator of transcription (STAT), sma and mad related protein (SMAD), chicken 
ovalbumin upstream promoter transcription factor (COUTP-TF), and retinoid X receptor 
(RXR).  To determine transcription factor(s) binding to GRE from the sequence analysis 
results, EMSAs were performed with αT3-1 nuclear extracts, radiolabeled probe 
containing -290/-270 region of the porcine GnRHR promoter, and non-labeled 
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oligonucleotides generated from the consensus sequence for each of the putative binding 
sites as a competitor.  Although ER consensus oligonucleotides competed with the probe 
for binding to GRE, we were unable to identify protein(s) comprising the specific binding 
complex following addition of antibodies to EMSAs (Figure 4.6). Therefore, I mutated 
putative ER binding site, -279/-274 bp and investigated glucocorticoid responsiveness of 
the vector whether thie ER site is GRE or not (Figure 4.7).  However, the mutation vector 
maintained dexamethasone-induced promoter activity, indicating that glucocorticoid 
response element is located in different site  within -290/-270 bp other than putative ER 
binding site. 
 
Binding of GR and poly (ADP-ribose) polymerase-1 (PARP-1) induces 
dexamethasone responsiveness of the porcine GnRHR promoter.  Since we did not 
have any information regarding the binding protein(s), we needed to isolate the protein(s) 
from nuclear extracts of αT3-1 cells treated with vehicle or 100 nM dexamethasone.  We 
performed DNA-protein pull-down assays to separate protein(s) bound to probe 
containing the GRE from the nuclear extracts.  Purified samples were sent to the 
Nebraska Center for Mass Spectrometry (University of Nebraska-Lincoln, Lincoln, 
Nebraska) to identify the protein samples.  The mass spectrometry results from both pull-
downed samples showed several possible protein identifications (Figure 4.8 and 4.9).  
The primarly candidate protein was poly (ADP-ribose) polymerase-1 (PARP-1) in both 
vehicle and 100 nM dexamethasone treatment sample with the highest protein score, 
1104 and 1478, respectively (Figure 4.8 and 4.9). 
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Figure 4.4.  Transient transfection of αT3-1 cells with luciferase vectors containing 
sequential 5’ deletions of the full-length porcine GnRHR promoter.  αT3-1 cells were 
transfected with pGL3 constructs containing 5000, 1900, 1400, 1000, 500, 320, 270, 190, 
170 and 150 bp of proximal promoter, or promoterless control. After 12 h, cells were 
treated with 100 nM dexamethasone for 12 h. Reduction of proximal promoter from 320 
to 270 bp inhibited glucocorticoid-stimulated luciferase activity by 50%, indicating the 
presence of a glucocorticoid response element(s). 
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Figure 4.5.  Transient transfection of αT3-1 cells with luciferase vectors containing 
sequential 5’ deletions of the full-length porcine GnRHR promoter.  Transient 
transfections were performed as shown in A with vectors containing 320, 290, 270, and 
190 bp of 5’ flanking sequence to more precisely locate the glucocorticoid response 
element(s). Results indicate glucocorticoid response element(s) is located between 270 
and 290 bp upstream of the translational start site. Bars with different superscripts differ 
(P < 0.05). 
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Figure 4.6.  EMSA using a radiolabeled probe corresponding to the -290/-270 bp region 
of the porcine GnRHR promoter. A, Nuclear extracts (5 µg) from αT3-1 cells treated with 
vehicle or 100 nM dexamethasone were incubated with a radiolabeled probe spanning the 
-290/-270 region of the porcine GnRHR promoter.  To determine the specificity of DNA-
protein interactions, we added 50-fold molar excess of unlabeled homologous and 
heterologous probe or unlabeled oligonucleotides containing consensus sequences for 
specific transcription factor binding sites as competitors. Binding reactions were 
subjected to electrophoresis through polyacrylamide gels as described in Materials and 
Methods. Increased binding was detected for nuclear extracts from αT3-1 cells treated 
with 100 nM dexamethasone compared to those treated with vehicle (70% ethanol). B, 
EMSA was performed with PR, ER, and GR consensus oligonucleotides. In addition, 
nuclear extracts were incubated with antibodies (1 ug) directed against either ER or 
normal rabbit IgG before the addition of radiolabeled probe. However, the ER antibody 
did not alter the specific binding complex. C, EMSA was performed with antibodies 
directed against GR or poly (ADP-ribose) polymerase (PARP). Arrow indicates supershit 
complex. Both PARP and GR antibodies generated a supershift of the specific binding 
complex, whereas a combination of PARP and GR antibodies abolished the supershift 
generated from the specific binding complex. 
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Figure 4.7.   Mutation of ER binding site on the porcine GnRHR promoter.  The mutation 
vector maintained dexamethasone-induced promoter activity, indicating that 
glucocorticoid response element is located in different site  within -290/-270 bp other 
than putative ER binding site. 
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A 
 
Database    : NCBInr 20100601 (11112683 sequences; 3786819628 residues) 
Taxonomy    : Mus. (147782 sequences) 
Timestamp   : 10 Jun 2010 at 21:03:20 GMT 
Protein hits: gi|20806109   poly [ADP-ribose] polymerase 1 [Mus musculus] 
  gi|387397   epidermal keratin subunit I [Mus musculus] 
  gi|4159806   type II keratin subunit protein [Mus musculus] 
  gi|12843914   unnamed protein product [Mus musculus] 
  gi|16303309   type II keratin 5 [Mus musculus] 
  gi|148672085   mCG144996 [Mus musculus] 
  gi|13272554   cytokeratin KRT2-6HF [Mus musculus] 
  gi|22164776   keratin, type II cytoskeletal 79 [Mus musculus] 
  gi|46485130   TPA: TPA_exp: keratin Kb40 [Mus musculus] 
  gi|511654   keratin type II [Mus musculus] 
  gi|398168   keratin 2 epidermis [Mus musculus] 
  gi|741022   keratin 15 
  gi|6754480   keratin, type I cytoskeletal 13 [Mus musculus] 
  gi|6730310   Chain A, Crystal Structure Of The Arf-Gap Domain And Ankyrin Repeats Of Papbeta 
  gi|74213106   unnamed protein product [Mus musculus] 
  gi|85701680   keratin, type II cytoskeletal 2 oral [Mus musculus] 
  gi|7106335   keratin, type I cytoskeletal 17 [Mus musculus] 
 
B 
Match to: gi|20806109; Score: 1104; poly [ADP-ribose] polymerase 1 [Mus 
musculus] 
Nominal mass (Mr): 113506; Calculated pI value: 9.06 
Taxonomy: Mus musculus 
Sequence Coverage: 41% 
Matched peptides shown in Bold 
 
     1  MAEASERLYR  VEYAKSGRAS  CKKCSESIPK  DSLRMAIMVQ  SPMFDGKVPH  
    51  WYHFSCFWKV  GHSIRQPDVE  VDGFSELRWD  DQQKVKKTAE  AGGVAGKGQD  
   101  GSGGKAEKTL  GDFLAEYAKS  NRSMCKGCLE  KIEKGQMRLS  KKMVDPEKPQ  
   151  LGMIDRWYHP  TCFVKKRDEL  GFRPEYSASQ  LKGFSLLSAE  DKEALKKQLP  
   201  AIKNEGKRKG  DEVDGTDEVA  KKKSKKGKDK  DSSKLEKALK  AQNELIWNIK  
   251  DELKKACSTN  DLKELLIFNQ  QQVPSGESAI  LDRVADGMAF  GALLPCKECS  
   301  GQLVFKSDAY  YCTGDVTAWT  KCMVKTQNPS  RKEWVTPKEF  REISYLKKLK  
   351  VKKQDRIFPP  ESSAPAPLAL  PLSVTSAPTA  VNSSAPADKP  LSNMKILTLG  
   401  KLSQNKDEAK  AVIEKLGGKL  TGSANKASLC  ISTKKEVEKM  SKKMEEVKAA  
   451  NVRVVCEDFL  QDVSASTKSL  QELLSAHSLS  SWGAEVKAEP  GEVVAPKGKS  
   501  AAPSKKSKGA  VKEEGVNKSE  KRMKLTLKGG  AAVDPDSGLE  HSAHVLEKGG  
   551  KVFSATLGLV  DIVKGTNSYY  KLQLLEDDKE  SRYWIFRSWG  RVGTVIGSNK  
   601  LEQMPSKEDA  VEHFMKLYEE  KTGNAWHSKN  FTKYPKKFYP  LEIDYGQDEE  
   651  AVKKLTVKPG  TKSKLPKPVQ  ELVGMIFDVE  SMKKALVEYE  IDLQKMPLGK  
   701  LSRRQIQAAY  SILSEVQQAV  SQGSSESQIL  DLSNRFYTLI  PHDFGMKKPP  
   751  LLNNADSVQA  KVEMLDNLLD  IEVAYSLLRG  GSDDSSKDPI  DVNYEKLKTD  
   801  IKVVDRDSEE  AEVIRKYVKN  THATTHNAYD  LEVIDIFKIE  REGESQRYKP  
   851  FRQLHNRRLL  WHGSRTTNFA  GILSQGLRIA  PPEAPVTGYM  FGKGIYFADM  
   901  VSKSANYCHT  SQGDPIGLIL  LGEVALGNMY  ELKHASHISK  LPKGKHSVKG  
   951  LGKTTPDPSA  SITLEGVEVP  LGTGIPSGVN  DTCLLYNEYI  VYDIAQVNLK  
  1001  YLLKLKFNFK  TSLW 
 
Figure 4.8.  MALDI-TOF MS identification of DNA pull-down protein extracted from 
αT3-1 cells treated with vehicle.  A shows protein hits from mouse sequence in NCBI 
database (147782 sequences). Protein hits are listed in descending order of MOWSE 
score.  B shows highest matching protein based on MOWSE score, molecular mass, and 
sequence coverage. 
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A 
 
Database    : NCBInr 20100601 (11112683 sequences; 3786819628 residues) 
Taxonomy    : Mus. (147782 sequences) 
Timestamp   : 10 Jun 2010 at 21:11:58 GMT 
Protein hits: gi|20806109   poly [ADP-ribose] polymerase 1 [Mus musculus] 
   gi|4159806   type II keratin subunit protein [Mus musculus] 
   gi|12859782   unnamed protein product [Mus musculus] 
   gi|387397   epidermal keratin subunit I [Mus musculus] 
   gi|9910294   keratin, type II cytoskeletal 71 [Mus musculus] 
   gi|741022   keratin 15 
   gi|46485130   TPA: TPA_exp: keratin Kb40 [Mus musculus] 
   gi|52789   unnamed protein product [Mus musculus] 
   gi|22164776   keratin, type II cytoskeletal 79 [Mus musculus] 
   gi|13272554   cytokeratin KRT2-6HF [Mus musculus] 
   gi|85701680   keratin, type II cytoskeletal 2 oral [Mus musculus] 
   gi|398168   keratin 2 epidermis [Mus musculus] 
   gi|7106335   keratin, type I cytoskeletal 17 [Mus musculus] 
 
 
B 
Match to: gi|20806109; Score: 1478; poly [ADP-ribose] polymerase 1 [Mus 
musculus] 
Nominal mass (Mr): 113506; Calculated pI value: 9.06 
Taxonomy: Mus musculus 
Sequence Coverage: 43% 
Matched peptides shown in Bold 
 
     1  MAEASERLYR  VEYAKSGRAS  CKKCSESIPK  DSLRMAIMVQ  SPMFDGKVPH  
    51  WYHFSCFWKV  GHSIRQPDVE  VDGFSELRWD  DQQKVKKTAE  AGGVAGKGQD  
   101  GSGGKAEKTL  GDFLAEYAKS  NRSMCKGCLE  KIEKGQMRLS  KKMVDPEKPQ  
   151  LGMIDRWYHP  TCFVKKRDEL  GFRPEYSASQ  LKGFSLLSAE  DKEALKKQLP  
   201  AIKNEGKRKG  DEVDGTDEVA  KKKSKKGKDK  DSSKLEKALK  AQNELIWNIK  
   251  DELKKACSTN  DLKELLIFNQ  QQVPSGESAI  LDRVADGMAF  GALLPCKECS  
   301  GQLVFKSDAY  YCTGDVTAWT  KCMVKTQNPS  RKEWVTPKEF  REISYLKKLK  
   351  VKKQDRIFPP  ESSAPAPLAL  PLSVTSAPTA  VNSSAPADKP  LSNMKILTLG  
   401  KLSQNKDEAK  AVIEKLGGKL  TGSANKASLC  ISTKKEVEKM  SKKMEEVKAA  
   451  NVRVVCEDFL  QDVSASTKSL  QELLSAHSLS  SWGAEVKAEP  GEVVAPKGKS  
   501  AAPSKKSKGA  VKEEGVNKSE  KRMKLTLKGG  AAVDPDSGLE  HSAHVLEKGG  
   551  KVFSATLGLV  DIVKGTNSYY  KLQLLEDDKE  SRYWIFRSWG  RVGTVIGSNK  
   601  LEQMPSKEDA  VEHFMKLYEE  KTGNAWHSKN  FTKYPKKFYP  LEIDYGQDEE  
   651  AVKKLTVKPG  TKSKLPKPVQ  ELVGMIFDVE  SMKKALVEYE  IDLQKMPLGK  
   701  LSRRQIQAAY  SILSEVQQAV  SQGSSESQIL  DLSNRFYTLI  PHDFGMKKPP  
   751  LLNNADSVQA  KVEMLDNLLD  IEVAYSLLRG  GSDDSSKDPI  DVNYEKLKTD  
   801  IKVVDRDSEE  AEVIRKYVKN  THATTHNAYD  LEVIDIFKIE  REGESQRYKP  
   851  FRQLHNRRLL  WHGSRTTNFA  GILSQGLRIA  PPEAPVTGYM  FGKGIYFADM  
   901  VSKSANYCHT  SQGDPIGLIL  LGEVALGNMY  ELKHASHISK  LPKGKHSVKG  
   951  LGKTTPDPSA  SITLEGVEVP  LGTGIPSGVN  DTCLLYNEYI  VYDIAQVNLK  
  1001  YLLKLKFNFK  TSLW 
 
Figure 4.9.  MALDI-TOF MS identification of DNA pull-down protein extracted from 
αT3-1 cells treated with 100 nM dexamesathone.  A shows protein hits from mouse 
sequence in NCBI database (147782 sequences). Protein hits are listed in descending 
order of MOWSE score.  B shows highest matching protein based on MOWSE score, 
molecular mass, and sequence coverage.  
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To confirm PARP-1 binding and demonstrate interaction between GR and PARP-
1 to the -290/-270 region of the porcine GnRHR promoter, EMSAs were performed with 
the addition of an antiserum directed against PARP-1 and GR to the specific binding 
complex for a probe spanning -290/-270 region of the promoter.  Addition of antibodies 
against GR and PARP-1 generated a supershift with nuclear extracts of αT3-1 cells 
treated with both vehicle or 100 nM dexamethasone (Figure 4.6).  Interestingly, the 
combination of antibodies specific for GR and PARP-1 abrogated the specific binding 
complex both control and 100 nM dexamethasone treated cells.  Thus, this result indicates 
GR and PARP-1 copoerate to regulate glucocorticoid responsiveness of the porcine 
GnRHR gene. 
The glucocorticoid receptor (GR) is phosphorylated via ERK1/2 and p38 
MAPK signaling pathways in αT3-1 cells.  Ligand binding to GR leads to 
phosphorylation of GR, stimulation GR signaling and glucocorticoid responsiveness of a 
target cell.  In order to examine which signaling pathway(s) were responsible for 
phosphorylation of GR underlying glucocorticoid responsiveness of the porcine GnRHR 
promoter, we transiently transfected αT3-1 cells with the full-length porcine GnRHR 
promoter and then treated with 100 nM dexamethasone in the presence or absence of  
SB202190, a p38 MAPK inhibitor, or U0126, a MEK1/2 inhibitor (Figure 4.10).  Both 
inhibitors reduced dexamethasone-induced luciferase activity of the porcine GnRHR 
promoter.  However, western blot results showed no changes of the phosphorylation of 
ERK and p38 MAPK during dexamethasone treatment (Figure 4.11). Interestingly, both 
ERK and p38 MAPK were already phosphorylated before dex treatment. This result 
indicates that ERK and p38 MAPK are not phosphorylated by GR signaling but they 
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phosphorylate GR to activate the GR translocation. This result is also consistent with 
Kotitschke et. al. (2009).  Next, to investigate the relevance of the PKC or PKA signaling 
pathways in glucocorticoid responsiveness of the porcine GnRHR promoter, we 
transiently transfected αT3 cells with the full-length porcine GnRHR promoter and then 
treated αT3 cells with 100 nM dexamethasone and either a PKC inhibitor (GF109203X),  
a PKA inhibitor (SQ22536), or combination of both (Figure 4.12). Neither inhibitor 
decreased dexamethasone-stimulated luciferase activity of the promoter.  Therefore,  
protein kinase A (PKA) and C (PKC) do not participate in GR activation and the 
glucocorticoid responsiveness of the porcine GnRHR gene, whereas p38 MAPK and 
ERK1/2 regulate glucocorticoid-induced promoter activity of the porcine GnRHR gene 
via GR phosphorylation. 
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Figure 4.10.  Signaling pathways underlying glucocorticoid responsiveness of the porcine 
GnRHR promoter.  αT3-1 cells were transiently transfected with the full length porcine 
GnRHR promoter. After 12 h, cells were treated with either SB202190 (p38 MAPK 
inhibitor) or U1206 (MEK1/2 inhibitor) 15 min prior to 100 nM dexamethasone 
treatment. Both inhibitors decreased dexamethasone-induced promoter activity. 
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Figure 4.11.   Phosphorylation of ERK and p38 MAPK during 100 nM dexamethasone 
treatment.  Western blot results showed no changes of the phosphorylation of ERK and 
p38 MAPK during dexamethasone treatment. Interestingly, both ERK and p38 MAPK 
were already phosphorylated before dex treatment. 
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Figure 4.12.  Signaling pathways underlying glucocorticoid responsiveness of the porcine 
GnRHR promoter.  Cells were transfected and treated with either GF109203X (PKC 
inhibitor) or SQ22536 (PKA inhibitor) as shown in A. Both inhibitors had no effect on 
dexamethasone-induced promoter activity. Bars with different superscripts differ (P < 
0.05).  
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Discussion 
 
Many studies have shown that hormones, including GnRH, estradiol, and 
progesterone induced responsiveness of the GnRHR gene.  For example, GnRH can up- 
or down-regulate the numbers of its receptor in the pituitary (McArdle et al., 1987; 
Uemura et al., 1992), and regulate GnRHR mRNA levels in pituitary cells of the rat 
(Kaiser et al., 1993; Bauer-Dantoin et al., 1995), sheep (Turzillo et al., 1995), and cow 
(Vizcarra et al., 1997).  Estradiol treatment of rat pituitary primary cultures can increase 
(long-term exposure) or decrease (short-term exposure) the number of GnRHRs (Menon 
et al., 1985; Emons et al., 1995).  In the ewe, exogenous estradiol consistently increased 
the number of GnRHRs both in vivo (Kirkpatrick et al., 1998) and in vitro (Gregg et al., 
1990; Laws et al., 1990).  On the other hand, administration of progesterone decreased 
GnRHR mRNA levels in the ovine pituitary (Bauer-Dantoin et al., 1995) as well as 
primary pituitary cultures from the sheep (Wu et al., 1994).  In addition to these 
hormones, glucocorticoids have also been implicated in the physiological regulation of 
GnRH and its receptor.  Chandran et al. (1994) reported that glucocorticoids act directly 
at the hypothalamus to suppress GnRH synthesis.  Dubey and Plant (1985) also 
demonstrated that glucocorticoids reduced the activity of the GnRH pulse-generating 
center within the hypothalamus.  Similarly, in the pituitary, glucocorticoids decreased 
GnRH responsiveness of the gonadotropes.  Although most studies have reported 
inhibitory effects of glucocorticoids on the production of the GnRHR, conflicting reports 
exist as others have demonstrated stimulatory effects. For example, glucocorticoids 
increased responsiveness of the mouse GnRHR gene (Maya-Núñez et al., 2003, 
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Kotitschke et al., 2009), GnRHR mRNA levels (5-fold; Turgeon et al., 1996), and 
gonadotropin subunit gene expression as well as gonadotropin secretion (Rosen et al., 
1991).   Thus, the mechanisms underlying glucocorticoid responsiveness of the GnRHR 
gene remain to be uncovered. 
In this present study, we determined dexamethasone responsiveness of the porcine 
GnRHR gene using transient transfections in mouse gonadotrope-derived αT3-1 cells.  
Further, we investigated the signaling mechanisms underlying the dexamethasone 
responsiveness of the porcine GnRHR gene.  Our results showed that dexamethasone 
activated the porcine GnRHR gene in a dose-dependent manner (Figure 4.1).  Moreover, 
we reported that the optimal dexamethasone treatment was 100 nM and this response was 
mediated by GR and its translocation to the nucleus (Figure 4.2 and 4.3).  Our 
observation that dexamethasone increased GnRHR promoter activity is consistent with 
previous reports.  Maya-Núñez and coworkers (2003) examined glucocorticoid 
responsiveness of the mouse GnRHR gene promoter.  In this study, dexamethasone 
activated the mouse GnRHR promoter in rat pituitary adenoma-derived GGH3 cells and 
this response was blocked by a glucocorticoid antagonist (RU 486).  Progressive 5’-
deletion study identified a putative glucocorticoid response element within the region -
331/-255 of the mouse GnRHR gene promoter and point mutation study revealed AP-1 as 
the glucocorticoid response element.  Further, they determined that this AP-1 element 
was directly associated with the c-Jun binding protein to increase dexamethasone induced 
gene expression of mouse GnRHR.  Like Maya-Núñez et al. (2003), we also utilized RU 
486 as a glucocorticoid antagonist to determine the specificity of the dexamethasone 
response by GR.  RU 486, however, was the prototype of antiprogestins which have 
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potential uses for contraception and for treatment of hormone-related pathological 
conditions such as breast cancer, endometriosis, and leiomyomata (Attardi et al., 2004).  
Moreover, the RU 486 and PR complex still binds to progesterone responsive elements 
(PREs) at the target gene, but this does not induce gene activation due to conformational 
changes of the complex (Baulieu, 1991; Kloosterboer et al., 1994).  Therefore, in order to 
confirm the specificity of the dexamethasone response mediated by not PR but GR, we 
utilized a new potent antiprogestagen, Org 31710 (Figure 4.2).  It has been reported that 
Org 31710 had almost similar to RU 486 in relative binding affinity to the cytoplasmic 
PR, and Org 31710, however, had above 30 fold lower binding to the GR than RU 486  
(Kloosterboer et al., 1994).  They also suggested that in vivo, Org 31710 appear to be 10 
fold more selective in antiprogestagenic effect than RU 486, which is mainly due to its 
low antiglucocorticoid activity.  In our experiments, Org 31710 functioned well as a 
potent antiprogestagen with no effect on dexamethasone induced porcine GnRHR gene 
promoter activity via GR.  Interesting result in that 1 nM Org 31710 abolished 
dexamethasone induced the promoter activity can be explained by its binding affinity to 
GR.  It is because increasing amount of Org 31710 can increase binding to GR and 
reduce GR function even though it has 30 times less binding affinity than RU 486.   This 
was confirmed by that 10 times more Org 31710 was required than RU 486 to remove 
dexamethasone stimulated promoter activity (Figure 4.1 and 4.2). 
It has been well established that the GR resides in the cytoplasm in an unliganded 
state and the presence of glucocorticoid results in cytoplasmic liganded GR translocation 
to nucleus (Wikstrom et al., 1987; Picard and Yamamoto, 1987).  Our western blot 
analysis result supported this statement, showing predominant appearance of GR protein 
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in the nucleus than in the cytoplasm after dexamethasone treatment (Figure 4.3).  In the 
absence of glucocorticoid, unliganded GR exists as an oligomer associated with the 
chaperone complex including hsp90, hsp70, p23 and one hsp90-binding tetratricopeptide 
repeat (TPR) protein in the cytoplasm (Pratt et al., 2004).  hsp90 binds to the GR ligand-
binding domain, which leads to open the ligand binding cleft and maintains the GR in a 
conformation suitable for ligand-binding (Picard et al., 1990; Pratt et al., 2006).  The 
hsp90 chaperone machinery is also required for the translocation of the ligand-GR 
complex into the nucleus (Pratt et al., 2006).  Upon ligand-binding, the GR undergoes a 
conformational change and hyperphosphorylation, and subsequently move within the 
nucleus to their sites of action (Avenant et al., 2010; Czar et al., 1997).  Translocation of 
ligand-GR complex is mediated by nuclear localization signal (NLS) sequences in the 
receptors themselves (Picard and Yamamoto, 1987) and bidirectional shuttling of 
receptors into and out of the nucleus occurs constantly (Guichon-Mantel et. al., 1991; 
Chandran and DeFranco, 1992; Madan and DeFranco, 1993; Dauvois et al., 1993).  
Studies of mechanisms on the nuclear localization of the cytoplasmic steroid receptors 
have demonstrated two different mechanisms.  The most efficient mechanism is rapid  
with less than 5 min half-life and depends on the hsp90-FKBP52-based heterocomplex 
(Davies et al., 2002; Galigniana et al., 2002; Gallo et al., 2007; Harrell et al., 2004; 
Pilipuk et al., 2007).   The alternative mechanism is hsp90 independent with about 40 to 
60 min half-life, which allows the formation of degradasomes and the subsequent 
targeting of the receptor to proteasomal degradation (Galigniana et al., 2004).  In contrast 
to the translocation of the receptor to the nucleus, GR cycles back very slowly to the 
cytoplasm with 8 to 12 hour upon steroid withdrawal (Galigniana et al., 1998). 
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Once the nuclear localization of ligand-GR complex occurs, the active GR can 
directly bind to either positive GREs that lead transcription activation or negative GREs 
that direct transcription repression on DNA to regulate target gene expression (Lu and 
Cidlowski, 2006).  In addition, the active GR interacts with transcription factors to either 
enhance or repress the transcription of target genes by interfering with or modifying the 
actions of the GR partners (Lu and Cidlowski, 2006; Lu and Cidlowski, 2004).  The GR 
can recruit a variety of proteins such as co-activators, co-repressors and chromatin 
remodeling complexes, depending on the cell type and promoter context to result in 
transactivation or transrepression (McKenna et al., 1999; Lu and Cidlowski, 2006; 
Avenant et al., 2010).  Therefore, to localize the GRE(s) within the porcine GnRHR 
promoter that is responsible for glucocorticoid responsiveness via GR-mediated 
transcriptional activation, we performed transfection assays with reporter vector 
containing sequential deletion of 5’ flanking sequences for the porcine GnRHR gene 
(Figure 4.4).  These data suggested that the regions -320 to -270 are responsible for 
dexamethasone-induced porcine GnRHR activity and there is/are important element(s), 
GRE(s), within the regions.   Further investigations by EMSA revealed more precise 
location of GRE, showing increased binding to the nuclear extracts from dexamethasone 
treated αT3-1 cells compared to vehicle (Figure 4.6) as well as by transfection assays 
(Figure 4.5).  Interestingly, the result of EMSA from the binding competition based on 
sequence analysis showed that instead of GR, ER bound to GRE (Figure 4.6).  However, 
supershift assay using ER antibody did not generate ER-antibody binding complex with 
the probe containing -290 to -270.  Taken together, our findings suggested that the 
porcine GnRHR promoter does not have GRE, and the GR, thus, does not bind directly to 
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the promoter but rather via GR-protein interaction or nongenomic signaling without GR-
DNA binding to regulate dexamethasone-stimulated responsiveness on the porcine 
GnRHR gene.  In addition to GR, ER and PR, sequence analysis of the regions -290 to -
270 has indicated several putative transcription factor binding sites including STAT, 
SMAD, COUP-TF, GATA, and Pit-1.  Unfortunately, we were unable to identify 
protein(s) comprising the specific binding complex following addition of antibodies to 
EMSAs (data not shown).  We assumed that it is because limitation of sequence analysis 
database, TRANSFAC
®
 public 6.0 which provides data on transcription factors, their 
experimentally-proven binding sites, consensus binding sequences and regulated genes in 
eukaryotes.  Thus, we directly isolated transcription factor(s) from the complex with the 
regions -290 to -270 of the promoter by DNA-protein pull-down assay and SDS-PAGE, 
and then identified the protein(s) using mass spectrometry.  Results from the experiments 
showed a novel transcription factor, PARP-1 which interacts with GR in αT3-1 cells 
(Figure 4.8 and 4.9) and were confirmed with super shift assay using the specific 
antibody to PARP-1 (Figure 4.6).  Our interesting finding of GR-PARP-1 interaction was 
supported by Muthumani et al. (2006).  They reported that the 96-amino acid viral protein 
R (Vpr) of HIV-1, which functions as a vital accessory gene by regulating various 
cellular functions, uses the GR pathway as a recruitment vehicle for the NF-κB co-
activating protein, PARP-1.  They also mentioned that the interaction of Vpr with GR 
may lead to conformational changes within the complex to expose binding sites for the 
PARP-1 but dexamethasone treatment, however, is insufficient to recruit PARP-1 and 
interact with GR.  Although their indication that the GR association with PARP-1 is a 
gain of function which is solely attributed to HIV-1 Vpr is different with our observation, 
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we believe that we are the first group to prove direct interaction of GR with PARP-1 on 
the porcine GnRHR gene promoter and it is cell specific event.  However, it still remains 
to be determined to understand the details of this regulation in vitro and in vivo.  
PARP is a nuclear enzyme that catalyzes the transfer of ADP-ribose units utilizing 
NAD
+
 as a substrate to various nuclear proteins (de Murcia et al., 1994; Lindahl et al., 
1995).  PARP-1 is the most abundant and ubiquitous member of this family including 
PARP-1, -2, -3, v-PARP, and tankyrase (Smith et al., 1998; Ame et al., 1999; Johansson, 
1999; Kickhoefer et al., 1999).  PARP-1 has been implicated in several catalytic activities 
and biological processes, including DNA replication (Simbulan-Rosenthal et al., 1998), 
HIV replication (Cole et al., 1991), DNA repair (de Murcia et al., 1994), carcinogenesis 
(Kun, 1998; Bauer et al., 1995), Chromatin remodeling (Gottschalk et al., 2009; Ahel et 
al., 2009), cell proliferation (Sakamaki et al., 2009; Pagano et al., 2007), and apoptosis 
(Boulares et al., 1999; Alano et al., 2010).  Further, several reports suggested a novel role 
for PARP-1 as a coactivator or repressor of transcription factors such as AP-1, SP-1, Oct-
1, YY-1, and STAT-1 that mediate the stress/inflammation response (Nie et al., 1998; 
Oei et al., 1997; Ha et al., 2002).  Consistent with these reports, in the present study, we 
determined that PARP-1 played a role as a coactivator showing that the anti-PARP-1 
antibody did not completely abolish the specific DNA-protein complex in the supershift 
assay, thus indicating that other transcription factors or coregulatory proteins may 
contribute to the complexes with PARP-1.  Therefore, we postulate that PARP-1 function 
as a member of the transcription machinery with GR to regulate the porcine GnRHR gene 
expression following dexamethasone treatment. 
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Although steroid hormones act as the primary signal in activating the receptor’s 
transcriptional regulatory functions, the phosphorylation of the receptors is also a 
mechanism to positively or negatively modulate receptor-mediated transcriptional 
responses (Ismaili and Garabedian, 2004).  Unliganded GR is phosphorylated and in the 
presence of glucocorticoid, GR becomes hyperphosphorylated by additional 
phosphorylation to result in translocation of ligand-binding GR to nucleus and 
transactivation or transrepression in gene expression (Wang et al., 2002; McKenna et al., 
1999).  As a first step toward the characterization of the signaling mechanisms effecting 
dexamethasone-induced translocation and transcriptional regulation of GR, we 
investigated the potential roles of MAPKs.  Our findings suggested that ERK1/2 and p38 
MAPK are responsible for dexamethasone induced promoter activity via GR 
phosphorylation (Figure 4.10 and 4.11).  Kurl and Jacob (1984) reported direct evidence 
for GR phosphorylation showing incubation of GR from rat liver cytosol with γ 32P-ATP 
and Mg
2+
 resulted in transfer of the radiolabeled phosphate to the GR.  Since that, many 
studies have been reported on ligand-dependent GR phosphorylation in vivo (Ortí et al., 
1989; Dalman et al., 1988) and Kaul et al. (2002) suggested the involvement of 
endogenous protein kinases during the phosphorylation event of GR from rat liver 
cytosol.  MAPKs respond to a variety of cellular stimuli such as growth factors, stress 
events, cytokines, and mitogens and, when they are activated, mediate diverse cellular 
processes including gene transcription, chromatin remodeling, apoptosis, and 
inflammation (Pearson et al., 2001).  Glucocorticoid-mediated GR phosphorylation via 
MAPKs has been studied intensively in many cells and  it has been suggested that this 
event is dependent on multiple kinases in a cell-, promoter-, and glucocorticoid-dose-
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dependent manner (Ismaili et al., 2004; Chen et al., 2008; Webster et al., 1997; Kino et 
al., 2007).  For example, JNK and ERK pathway have been involved in phosphorylation 
of the rat GR at Ser-246 or human GR at Ser-211 (equivalent to mouse GR Ser-234) as 
well as in dex-mediated transcription, showing direct role in GR phosphorylation and 
transcriptional regulation (Krstic et al., 1997; Rogatsky et al., 1998; Miller et al., 2007).  
In addition, Kotitschke et al. (2009) showed combinations of JNK, ERK, and p38 MAPK 
inhibitors decreased dex-induced phosphorylation of the endogenous mouse GR at Ser-
234 and suggested a complex interplay between MAPKs and possibly other kinases in 
response to dex treatment to modulate mouse GR phosphorylation and transcription in 
LβT2 cells. 
In conclusion, we demonstrated glucocorticoid responsiveness of the porcine 
GnRHR gene in αT3-1 cells and identified PARP-1 as a transcription factor responsible 
for this responsiveness.  In addition, we determined that this transcriptional regulation 
was mediated by ERK1/2 and p38 MAPK pathway, phosphorylating dex-bound GR.  
Finally, we suggested working model for the mechanisms underlying glucocorticoid 
regulation of the porcine GnRHR gene (Figure 4.13) Once glucocorticoid binds to GR in 
the cytoplasm, ERK and p38 MAPK phosphorylate and activate GR to activate, releasing 
heat shock protein (HSP). Phosphorylated, ligand-bound GRs are translocated to the 
nucleus and recruit poly (ADP-ribose) polymerase-1 (PARP-1) to bind to the 
glucocorticoid response element, activating the porcine GnRHR gene. 
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Figure 4.13.  Working model for the mechanisms underlying glucocorticoid regulation of 
the porcine GnRHR gene. Once glucocorticoid binds to GR in the cytoplasm, ERK and 
p38 MAPK phosphorylate and activate GR to activate, releasing heat shock protein 
(HSP). Phosphorylated, ligand-bound GRs are translocated to the nucleus and recruit 
poly (ADP-ribose) polymerase-1 (PARP-1) to bind to the glucocorticoid response 
element, activating the porcine GnRHR gene. 
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Appendix I 
 
 
 
 
In addition to glucocorticoid responsiveness, I determined progesterone 
responsiveness of the porcine GnRHR gene. The promoter showed increased 
progesterone-induced activity in a dose dependent manner and decreased activity by 
mifepristone. Whereas dexamethasone-stimulated promoter activity was blocked with 
100Pm mifepristone, progesterone-induced activity required 10,000 times more 
antagonist. This result also demonstrated further confirmation that dexamethasone 
responsiveness of the porcine GnRHR gene is mediated by GR, not PR. 
  
105 
Appendix II 
 
 
 
 
 
Our laboratory investigated breed differences on the porcine GnRH receptor 
promoters of Chinese Meishan, UNL Index, White crossbred line because each breed has 
different ovulation rate and litter size.  Transfection study showed that Meishan promoter 
was most highly expressed in aT3 cells compare to other two breeds.  In addition, we 
have identified polymorphism among the breeds. Therefore, because of these breed 
differences in cell specific expression, I examined breed differences on the 
glucocorticoids responsiveness. Reporter constucts containing either the Control, Index 
or Meishan GnRHR gene promoter responded equally (about 2-fold) to 100 nM 
dexamethasone treatment.  
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Appendix III 
 
 
 
 
In this study, I determined two cell specific expression factors binding to the 
porcne GnRHR gene promoter.  Previously, our lab found 2 SF-1 site located -1760/-
1753 and -179/-171.  I identified another SF-1 located between -315 and -307, and RXRα 
and β between -279 and -274.  Mutation of SF-1 site decreased basal expression of the 
porcine GnRHR gene about 30%, and however, mutation of RXR α and β site completely 
block the promoter activity.  In addition, I also determined that there is a repressor 
between -306 and -301.  Mutation of this site increased basal expression of the receptor 
gene about 17-fold.  
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